Vivli aims to advance human health through clinical research data sharing. One of the key ways we support this is through the Vivli platform, which facilitates data sharing. Vivli platform metrics as of 31 Dec 2024. The metrics will be updated every two months.
These tables provide details of approved research proposals that have published or presented their results.
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetrics Score |
|---|---|---|---|---|---|---|
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | Heerspink, H.J., Eddington, D., Chaudhari, J., Estacio, R., Imai, E., Goicoechea, M., Hannedouche, T., Haynes, R., Jafar, T.H., Johnson, D.W. and van Kruijsdijk, R.C., 2024. A meta-analysis of randomized controlled clinical trials implications of acute treatment effects on glomerular filtration rate for long-term kidney protection. Kidney International. Doi: 10.1016/j.kint.2024.05.024 | GlaxoSmithKline, Takeda | 19 |
| 4915 | Rachel Tomko | Medical University of South Carolina | Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy | Wolf, B.J., Gray, K.M., Dahne, J.R., Hashemi, D. and Tomko, R.L., 2024. Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial. Nicotine and Tobacco Research, p.ntae290. Doi: 10.1093/ntr/ntae290 | Pfizer | 0 |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Takase-Minegishi, K., Böhringer, S., Nam, J.L., Kaneko, Y., Behrens, F., Saevarsdottir, S., Detert, J., Leirisalo-Repo, M., van der Heijde, D., Landewé, R. and Ramiro, S., 2024. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatology, p.keae113. DoI: 10.1093/rheumatology/keae113 | AbbVie, Pfizer | 0 |
| 4926 | Eva-Maria Gamper | Medical University Innsbruck | Comparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its use | Pilz, M.J., Seyringer, S., Al-Naesan, I., King, M.T., Bottomley, A., Norman, R., Schlosser, L., Hell, T. and Gamper, E.M., 2024. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs. PharmacoEconomics-Open, pp.1-14. Doi: 10.1007/s41669-024-00484-9 | Boehringer Ingelheim | 3 |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V., Ravindranath, V., Arneson, D., Mosenia, A., Butte, A. and Wang, S., 2023. S936 Optimizing Treatment Selection in Crohn’s Disease Using Patient-Specific Features: An Individual Participant Data Meta-Analysis of Fifteen Randomized Controlled Trials. Official journal of the American College of Gastroenterology| ACG, 118(10S), pp.S701-S702. Doi: 10.1016/S0016-5085(24)03735-1 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 1 |
| 5435 | Matthew Gilbert | University of Vermont | Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled Trial | Gilbert, M.P., Skelly, J., Hernandez, A.F., Green, J.B., Krychtiuk, K.A., Granger, C.B., Leiter, L.A., McMurray, J.J., Del Prato, S. and Pratley, R.E., 2024. Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism. Doi: 10.1111/dom.15479 | GlaxoSmithKline | 18 |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | J. Wilk, V. Aggarwal, M. Pauley, D. Corey, D. Conrado, K. Lingineni, J. Morales, D. Yoon, J. Burton, J. Larkindale, S. Ma, C. Hovinga, T. Martinez, K. Romero, R. Belfiore-Oshan, S. Kim. A COMPUTATIONAL TOOL TO OPTIMIZE CLINICAL TRIAL DESIGN FOR DUCHENNE MUSCULAR DYSTROPHY: A PRACTICAL GUIDE AND CASE STUDIES. American Society for Clinical Pharmacology & Therapeutics. [See Browse by Poster Title tab]. Poster PII-179. 2024. | CureDuchenne | N/A |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Lees, J., Crowther, J., Hanlon, P., Butterly, E.W., Wild, S.H., Mair, F., Guthrie, B., Gillies, K., Dias, S., Welton, N.J. and Katikireddi, S.V., 2024. Participant characteristics and exclusion from phase 3/4 industry funded trials of chronic medical conditions: meta-analysis of individual participant level data. BMJ medicine, 3(1). Doi: 10.1136/bmjmed-2023-000732 | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB | 1 |
| 5921 | Paul Schulz | University of Texas Health Science Center | Identification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications | Wang, D., Ma, X., Schulz, P.E., Jiang, X. and Kim, Y., 2024. Clinical outcome-guided deep temporal clustering for disease progression subtyping. Journal of Biomedical Informatics, 158, p.104732. Doi: 10.1016/j.jbi.2024.104732 | Lilly | 1 |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Duarte, C., Ferreira, R.J., Welsing, P.M., Jacobs, J.W., Gossec, L., Machado, P.M., van der Heijde, D. and da Silva, J.A.P., 2024. Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?. RMD open, 10(1), p.e003972. Doi: 10.1136/rmdopen-2023-003972 | AbbVie, Pfizer, Roche, UCB | 2 |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Duarte, C., Jacobs, J.W., Ferreira, R.J., Welsing, P.M., Gossec, L., Machado, P.M., van der Heijde, D. and da Silva, J.A.P., 2024. Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data. RMD open, 10(4), p.e004387. Doi: 10.1136/rmdopen-2024-004387 | AbbVie, Pfizer, Roche, UCB | 1 |
| 6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Dubbelman, M.A., Vromen, E.M., Tijms, B.M., Berkhof, J., Ottenhoff, L., Vijverberg, E.G., Prins, N.D., van der Flier, W.M. and Sikkes, S.A., 2024. Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(3), p.e12485. Doi: 10.1002/trc2.12485 | Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly | 1 |
| 6471 | Vincent Lanting | University of Amsterdam Academic Medical Center | Risk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysis | Lanting, V., Takada, T., Bosch, F., Marshall, A., Grosso, M., Young, A., Lee, A.Y., Di Nisio, M., Raskob, G., Kamphuisen, P.W. and Buller, H.R., Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thrombosis and haemostasis. DOI: 10.1055/a-2418-3960 | Pfizer | 1 |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Krotka, P., Posch, M., Gewily, M., Höglinger, G. and Roig, M.B., 2024. Statistical modeling to adjust for time trends in adaptive platform trials utilizing non-concurrent controls. arXiv preprint arXiv:2403.14348. Doi: 10.48550/arXiv.2403.14348 | AbbVie | 1 |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Gewily, M., Plan, E.L., Yousefi, E., König, F., Posch, M., Hopfner, F., Höglinger, G. and Karlsson, M.O., 2024. Quantitative comparisons of progressive supranuclear palsy rating scale versions using item response theory. Movement Disorders. Doi: 10.1002/mds.30001 | AbbVie | 1 |
| 6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | Ahuja, D., Luo, J., Qi, Y., Syal, G., Boland, B.S., Chang, J., Ma, C., Jairath, V., Xu, R. and Singh, S., 2024. Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn’s Disease: Secondary Analysis of the PYRAMID Registry. Clinical Gastroenterology and Hepatology. Doi: 10.1016/j.cgh.2024.01.003 | AbbVie | 11 |
| 6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | Ahuja, D., Luo, J., Qi, Y., Syal, G., Boland, B., Chang, J., Ma, C., Jairath, V., Xu, R. and Singh, S., 2024. IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN’S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY. Inflammatory Bowel Diseases, S1(30), p.S1. Doi: 10.1093/ibd/izae020.001 | AbbVie | 1 |
| 6758 | Qian Chen | Hubei Cancer Hospital | Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy | Chen, Q., Yuan, S., Liu, N., Wang, H., Shang, X., Ma, X., Sun, Y., Wei, C., Liu, L., Wang, X. and Liu, Y. Effect of first-line bevacizumab on prognosis of second or later-line immunotherapy in patients with advanced non-squamous non-small cell lung cancer: A retrospective analysis. JCO 42, 20570. (2024). Doi:10.1200/JCO.2024.42.16_suppl.e20570 | Roche | N/A |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Ding, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Wang, G., Tang, J., Cao, J. and He, L., 2024. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial. Breast Cancer Research, 26(1), pp.1-10. Doi: 10.1186/s13058-023-01761-x | Roche | 12 |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, J.G., Yang, J., Wang, H., Wong, A.H.H., Tan, F., Chen, X., Shen, G., Wang, Y.J., Frey, B., Fietkau, R. and Hecht, M., Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy. Doi: 10.1136/bmjonc-2023-000128 | Bristol Myers Squibb, Project Data Sphere, Roche | 7 |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Xu, J., Wang, H., Zhang, C., Jin, S.H., Chen, X., Tan, F., Frey, B., Hecht, M., Sun, J.G., Gaipl, U.S. and Ma, H., 2024. Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC. iScience. Doi: 10.1016/j.isci.2024.111363 | Bristol Myers Squibb, Project Data Sphere, Roche | 2 |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | J. Shen, J. Ma, S. Chen, Q. Li, S. Jin, C. Zhang, H. Wang, X. Chen, F. Tan, X. Tian, H. Zhang, G. Pan, U. Gaipl, H. Ma, J. Zhou. Quality of life scale-based machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer. 2024. Annals of Oncology (2024) 35 (suppl_2): S1197-S1204. Doi: 10.1016/annonc/annonc1586 | Bristol Myers Squibb, Project Data Sphere, Roche | N/A |
| 6762, 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, J.G., Xu, J., Wang, H., Zhang, C., Jin, S.H., Chen, X., Tan, F., Frey, B., Hecht, M., Gaipl, U.S. and Ma, H., 2024. Efficacy of Radiotherapy Combined with Atezolizumab or Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer: A PSM-IPTW Cohort Study. International Journal of Radiation Oncology, Biology, Physics, 120(2), pp.e89-e90. Doi: 10.1016/j.ijrobp.2024.07.1979 | Bristol Myers Squibb, Project Data Sphere, Roche | 1 |
| 6860 | Nicholas Lange | Columbia University | Belatacept in obese kidney transplant recipients | Lange, N.W., King, K., Husain, S.A., Salerno, D.M., Tsapepas, D.S., Hedvat, J., Yu, M. and Mohan, S., 2024. Obesity is associated with a higher incidence of rejection in patients on belatacept: a pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials. American Journal of Transplantation. Doi: 10.1016/j.ajt.2024.02.015 | Bristol Myers Squibb | 4 |
| 6866 | Andy Lim | Monash University | Meta-analysis of early stroke recurrence rate in minor stroke | Lim, A., Ma, H., Johnston, S.C., Singhal, S., Muthusamy, S., Wang, Y., Pan, Y., Coutts, S.B., Hill, M.D., Ois, A. and Kapral, M.K., 2023. Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies. Journal of the American Heart Association, p.e032471. Doi: 10.1161/JAHA.123.032471 | AstraZeneca | 8 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica, B., Romiti, G.F., Proietti, M., Mei, D.A., Boriani, G., Ding, W.Y., Olshansky, B., Huisman, M.V. and Lip, G.Y.H., 2024. Early rhythm control in patients with recently diagnosed atrial fibrillation: findings from the GLORIA-AF Registry Phase III. Europace, 26(Supplement_1), pp.euae102-066. Doi: 10.1093/europace/euae102.066 | Boehringer Ingelheim | 1 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Lam, S.H.M., Romiti, G.F., Olshansky, B., Chao, T.F., Huisman, M.V. and Lip, G.Y.H., 2024. Combination therapy of beta-blockers and digoxin is associated with increased risk of major adverse cardiovascular events and all-cause mortality in patients with atrial fibrillation: a report from the GLORIA–AF registry. Internal and Emergency Medicine, pp.1-10. Doi: 10.1007/s11739-024-03629-0 | Boehringer Ingelheim | 3 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Ishiguchi, H., Abdul-Rahim, A.H., Huang, B. et al. Residual Risks of Thrombotic Complications in Anticoagulated Patients with Atrial Fibrillation: A Cluster Analysis Approach from the GLORIA-AF Registry. J GEN INTERN MED (2024). Doi: 10.1007/s11606-024-09045-6 | Boehringer Ingelheim | 6 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Liu, Y., Chen, Y., Lam, S.H., Huang, B., Romiti, G.F., Alam, U., Chao, T.F., Olshansky, B., Hong, K., Huisman, M.V. and Lip, G.Y., 2024. Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA‐AF registry phase III. Diabetes, Obesity and Metabolism, 26(12), pp.5795-5804. Doi: 10.1111/dom.15950 | Boehringer Ingelheim | 2 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Li, M., Huang, B., Lam, S.H.M., Ishiguchi, H., Liu, Y., Olshansky, B., Huisman, M.V., Chao, T.F. and Lip, G.Y., 2024. Long‐term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer: A report from the GLORIA‐AF registry. European Journal of Clinical Investigation, p.e14347. Doi: 10.1111/eci.14347 | Boehringer Ingelheim | 1 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Huang, B., Lam, H.M., Ishiguchi, H., Liu, Y., Chao, T.F., Olshansky, B., Huisman, M. and Lip, G., 2024. Temporal trends and regional differences of initial oral antiarrhythmic drug options in patients with new-onset atrial fibrillation: a report from the GLORIA-AF registry. European Heart Journal, 45(Supplement_1), pp.ehae666-3319. Doi: 10.1093/eurheartj/ehae666.3319 | Boehringer Ingelheim | 0 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Huang, B.I., Li, M., Liu, Y., Lam, H.M., Ishiguchi, H., Chao, T.F., Olshansky, B., Huisman, M. and Lip, G., 2024. Incidence, characteristics, and prognostic impact of cancers in patients with atrial fibrillation: a report from the GLORIA-AF registry. European Heart Journal, 45(Supplement_1), pp.ehae666-3154. Doi: 10.1093/eurheartj/ehae666.3154 | Boehringer Ingelheim | 0 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Liu, Y., Chen, Y., Lam, S.H.M., Huang, B., Chao, T.F., Olshansky, B., Huisman, M. and Lip, G.Y.H., 2024. Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: implications of insulin treatment: a report from the GLORIA-AF Registry Phase III. European Heart Journal, 45(Supplement_1), pp.ehae666-463. Doi: 10.1093/eurheartj/ehae666.463 | Boehringer Ingelheim | 0 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Liu, Y., Chen, Y., Lam, S.H.M., Huang, B., Chao, T.F., Olshansky, B. and Lip, G.Y.H., 2024. Implications of renal function on adverse clinical events in patients with atrial fibrillation: a comparative analysis of VKA and NOAC therapy-Insights from the GLORIA-AF Registry Phase III. European Heart Journal, 45(Supplement_1), pp.ehae666-603. Doi: 10.1093/eurheartj/ehae666.603 | Boehringer Ingelheim | 0 |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | Gunter, S.J., Holcomb, Z.E., Lam, B.D., Porter, M.L. and Kimball, A.B., 2024. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab. JAMA dermatology. Doi: 10.1001/jamadermatol.2024.1075 | AbbVie | 3 |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | Gunter, S.J., Porter, M.L. and Kimball, A.B., 2024. Placebo responders with moderate-to-severe hidradenitis suppurativa experience declines in inflammation as measured by C-reactive protein: a post hoc analysis of two double-blinded, randomized-controlled trials. International Journal of Women's Dermatology, 10(3), p.e171. Doi: 10.1097/JW9.0000000000000171 | AbbVie | 1 |
| 7142 | Sara Tedeschi | Brigham and Women’s Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Tedeschi, S.K., Hayashi, K., Zhang, Y., Choi, H. and Solomon, D.H., 2024. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. Annals of the Rheumatic Diseases. Doi: 10.1136/ard-2024-225761 | Takeda | 12 |
| 7156 | Angelina Tjokrowidjaja | University of Sydney | Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis | Tjokrowidjaja, A., Friedlander, M.L., Ledermann, J.A., Coleman, R.L., Mirza, M.R., Matulonis, U.A., Pujade-Lauraine, E., Lord, S.J., Scott, C.L., Goble, S. and York, W., 2024. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly (ADP-ribose) Polymerase Inhibitor. Journal of Clinical Oncology, JCO-23. Doi: 10.1200/JCO.23.01182 | AstraZeneca | 31 |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | Kerr, W.T., Kok, N., Reddy, A.S., McFarlane, K.N., Stern, J.M., Pennell, P.B., Stacey, W. and French, J., 2024. Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications. Neurology, 103(4), p.e209713. Doi: 10.1212/WNL.0000000000209713 | GlaxoSmithKline, Johnson & Johnson, UCB | 1 |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Chhibba, T., Wong, E.C., Reinisch, W., Targownik, L. and Narula, N., 2024. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY. European Journal of Gastroenterology & Hepatology, 36(6), pp.704-711. Doi: 10.1097/MEG.0000000000002759 | Takeda | 1 |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Guo, T., Zhou, Y., Liang, F., Wang, Z., Bourbonne, V., Käsmann, L., Sundahl, N., Wu, A.J.C., Ni, J. and Zhu, Z., 2024. Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials. Translational Lung Cancer Research, 13(1), p.126. Doi: 10.21037/tlcr-23-792 | Roche | 1 |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Zhou, Y., Guo, T., Liang, F., Wang, Z., Zhang, J., Ni, J. and Zhu, Z., 2024. Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150. Cancer. Doi: 10.1002/cncr.35242 | Roche | 5 |
| 7400 | Aryelly Rodriguez | The University of Edinburgh | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | Rodriguez, A., Williams, L.J., Lewis, S.C., Sinclair, P., Eldridge, S., Jackson, T., and Weir, C.J. Using re-identification risk scores on publicly available anonymised clinical trial datasets. ICTMC 2024. Abstract PS.8B-3. 2024. | GlaxoSmithKline, UCB | N/A |
| 7493 | Nina Hilkens | Radboudumc Nijmegen | Blood pressure variability and progression of white matter hyperintensities after ischemic strokes | Hilkens, N.A., de Leeuw, F.E., Klijn, C.J. and Richard, E., 2024. Blood pressure variability and white matter hyperintensities after ischemic stroke. Cerebral Circulation-Cognition and Behavior, p.100205. Doi: 10.1016/j.cccb.2024.100205 | Boehringer Ingelheim | 1 |
| 7549 | Vipul Jairath | Alimentiv Inc | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | Solitano, V., Panaccione, R., Sands, B.E., Wang, Z., Zou, G., Peyrin-Biroulet, L., Danese, S., Cornfield, L.J., Feagan, B.G., Singh, S. and Jairath, V., 2024. P280 Comparative responsiveness of disease activity indices in moderately-to-severely active Ulcerative Colitis: a post-hoc analysis of the UNIFI trial. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i647-i648. Doi: 1093/ecco-jcc/jjad212.0410 | AbbVie, Johnson & Johnson, Takeda | 1 |
| 7549 | Vipul Jairath | Alimentiv Inc | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | V. Solitano, R. Panaccione, B. E. Sands, S. Singh, V. Jairath, C. Ma. Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis. 2024. Preprint. Med. Doi: 10.1016/j.medj.2024.09.001 | AbbVie, Johnson & Johnson, Takeda | 1 |
| 7587 | Yashmin Karten | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran S., Karten Y., Cullen N., Lau C., Priest E., White H., Irizarry M. DE-RISKING CLINICAL TRIAL DESIGN VIA MODEL-INFORMED DRUG DEVELOPMENT WITH THE CRITICAL PATH FOR ALZHEIMER’S DISEASE CONSORTIUM. Alzheimer's & Parkinson's Diseases Conference. Abstract Shift 2-0149. 2024. | Lilly | N/A |
| 7587 | Yashmin Karten | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran, S., Priest, E., Lau, C., Irizarry, M.C. and Karten, Y., 2024, July. Critical Path for Alzheimer’s Disease (CPAD) Consortium: Data-Driven Solutions for Clinical Trial Design and Informed Decision Making. In Alzheimer's Association International Conference. ALZ. | Lilly | N/A |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment | Parent N, Hopkins AM, Sorich MJ. Machine learning for enhanced survival prediction from tumour growth inhibition data. Population Approach Group of Australia and New Zealand (PAGANZ). Oral Presentation. 2024. | Roche | N/A |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment | Li LX, Hopkins AM, Sorich MJ. Methodologically appropriate evaluation of continuous BMI as a clinical predictor of chemoimmunotherapy efficacy in advanced non-small cell lung cancer. Population Approach Group of Australia and New Zealand (PAGANZ). Oral Presentation. 2024. | Roche | N/A |
| 7598 | Harry Southworth | Data Clarity Consulting Ltd | Exploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data mining | Southworth H., Schubiner H. Statistical investigation of comorbidities of back pain in the medical history data from clinical trials of healthy subjects. 2024. Open Science Framework (OSF). Doi: 10.17605/OSF.IO/APXUT | AstraZeneca, GlaxoSmithKline | 1 |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Wang, Q. and Hong, H., 2024. Bayesian hierarchical models with calibrated mixtures of g-priors for assessing treatment effect moderation in meta-analysis. arXiv preprint arXiv:2410.24194. Doi: 10.48550/arXiv.2410.24194 | Johnson & Johnson, Lundbeck, Takeda | 2 |
| 7601 | Guru Sonpavde | AdventHealth Cancer Institute | Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitors | Graser, C., McDonald, T.O., Sonpavde, G. and Michor, F., 2024. Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab. Cancer Research, 84(6_Supplement), pp.2392-2392. Doi: 10.1158/1538-7445.AM2024-2392 | Roche | 1 |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Salter, A., Lancia, S., Fitzgerald, K., Ann Marrie, R., 2024. Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations. Neurology. 102(5). doi: 10.1212/WNL.0000000000209135 | Roche | 5 |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Salter, A., Lancia, S., Kowalec, K., Fitzgerald, K.C. and Marrie, R.A., Comorbidity and Disease Activity in Multiple Sclerosis. JAMA neurology. Doi: 10.1001/jamaneurol.2024.2920 | Roche | 76 |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Salter, A., Lancia, S., Fitzgerald, K., Kowalec, K., Marrie, R. A. The Association of Comorbidities and Disease Activity in Phase III Clinical Trials for Disease-Modifying Therapies in Multiple Sclerosis. ECTRIMS 2024. Multiple Sclerosis Journal. 2024;30(3_suppl):4-124. Doi: 10.1177/13524585241269218 | Roche | 15 |
| 7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | Narula, N., Hamam, H., Wong, E.C., Marshall, J.K., Jairath, V., Hanauer, S.B., Reinisch, W. and Dulai, P.S., 2024. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i1308-i1308. Doi: 10.1093/ecco-jcc/jjad212.0819 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 1 |
| 7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | Narula, N., Hamam, H., Liu, J., Wong, E.C., Marshall, J.K., Jairath, V., Hanauer, S.B., Reinisch, W. and Dulai, P.S., 2024. Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in clinical trials of ulcerative colitis. Journal of Crohn's and Colitis, p.jjae092. Doi: 10.1093/ecco-jcc/jjae092 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 22 |
| 7662 | Benoit You | Université Claude Bernard Lyon | Prognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) | A. Carrot, A., Oudard, S., Fizazi, K., Maillet, D., Sartor, O., Freyer, G., You, B. Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA. JCO Clin Cancer Inform 8, e2300208(2024). DOI :10.1200/CCI.23.00208 | Sanofi | 1 |
| 7663, 7385 | Amit Etkin | Alto Neuroscience, Inc. | Cognitive predictors of antidepressant treatment outcome in patients with major depressive disorder | Jordan, J.T., Shen, L., Cooper, N.J., Goncalves, S.V., Trivedi, M.H., Schatzberg, A.F., Wu, W., Savitz, A.J. and Etkin, A., 2024. Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled Trials. The Journal of Clinical Psychiatry, 85(4), p.56760. Doi: 10.4088/JCP.24m15295 | Lilly, Lundbeck, Takeda | 22 |
| 7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis | Tadount, F., Kiely, M., Assi, A., Rafferty, E., Sadarangani, M., MacDonald, S.E. and Quach, C., 2024, April. Sex Differences in the Immunogenicity and Efficacy of Seasonal Influenza Vaccines: A Meta-analysis of Randomized-Controlled Trials. In Open Forum Infectious Diseases (p. ofae222). Oxford University Press. Doi: 10.1093/ofid/ofae222 | Sanofi | 1 |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Matos, A., Henriques, C., Doria, A. and Inês, L.S., 2024. P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials. Doi: 10.1136/lupus-2024-el.181 | AstraZeneca | 1 |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L.S., 2024. P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials. Doi: 10.1136/lupus-2024-el.121 | AstraZeneca | 1 |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, D., Henriques, C., Matos, A., Doria, A. and Inês, L.S., 2024. O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials. Doi: 10.1136/lupus-2024-el.31 | AstraZeneca | 0 |
| 7811 | Gustavo Turecki | McGill University | Using Artificial Intelligence to Personalize Treatment Selection and Trajectory Monitoring of Bipolar Disorder | Mehltretter, J., Fratila, R., Perlman, K., Tunteng, J.-F., Popescu, C., Turecki, G., & Benrimoh, D. (2024). Using Artificial Intelligence to Personalize Initial Treatment Selection in Bipolar Depression. Zenodo. Doi: 10.5281/zenodo.12747378 | AbbVie, Lilly, Otsuka, Takeda | N/A |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | Xu, Y., Mallity, C., Collins, E., Siegal, D.M., Wang, T.F. and Carrier, M., 2024. Anticoagulation for the Prevention of Arterial Thromboembolism in Cancer Patients by Primary Tumor Site: A Systematic Review and Meta-Analysis of Randomized Trials. European Heart Journal-Cardiovascular Pharmacotherapy, p.pvae068. Doi: 10.1093/ehjcvp/pvae068 | GlaxoSmithKline, Sanofi | 0 |
| 7828 | Ramiro Sofia | Leiden University Medical Center | SPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | Benavent, D., Navarro-Compán, V., Capelusnik, D. and Ramiro, S., 2024. POS0799 EFFICACY OF BDMARDS IN EARLY VERSUS ESTABLISHED DISEASE IN AXIAL SPONDYLOARTHRITIS: A META-ANALYSIS OF RANDOMIZED TRIALS. Doi: 10.1136/annrheumdis-2024-eular.2352 | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB | 1 |
| 7844 | Linong Ji | Peking University People's Hospital | Risk stratification and responder identification for glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Type 2 Diabetes Mellitus (T2DM): a machine learning facilitated post-hoc analysis of clinical trials | HUANG, Q., ZOU, X., BOYKO, E.J. and JI, L., 2024. 925-P: Using Machine Learning to Predict Dynamic Cardiovascular Risks and Identify the Treatment Responses of Canagliflozin in Type 2 Diabetes Mellitus. Diabetes, 73(Supplement_1). Doi: 10.2337/db24-925-P | BioLINCC, GlaxoSmithKline, Johnson & Johnson | 1 |
| 7848 | Jennifer Lund | University of North Carolina at Chapel Hill | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Lund, J.L., Webster-Clark, M.A., Westreich, D., Sanoff, H.K., Robert, N., Frytak, J.R., Boyd, M., Shmuel, S., Stürmer, T. and Keil, A.P., 2024. Visualizing External Validity: Graphical Displays to Inform the Extension of Treatment Effects from Trials to Clinical Practice. Epidemiology, 35(2), pp.241-251. Doi: 10.1097/EDE.0000000000001694 | Sanofi | 1 |
| 7850 | Vipul Jairath | University of Western Ontario | Impact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel Disease | Ahuja, D., Zou, G., Solitano, V., Syal, G., Lee, H.H., Ma, C., Jairath, V. and Singh, S., 2024. No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis. Clinical Gastroenterology and Hepatology. Doi: 10.1016/j.cgh.2024.08.040 | AbbVie, Johnson & Johnson, Pfizer, Takeda, UCB | 9 |
| 7854 | Vipul Jairath | University of Western Ontario | Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials | Vuyyuru, S.K., Ma, C., Nguyen, T.M., Zou, G., Peyrin-Biroulet, L., Danese, S., Dulai, P., Narula, N., Singh, S. and Jairath, V., 2024. Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials. eClinicalMedicine, 72. Doi: 10.1016/j.eclinm.2024.102621 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 14 |
| 7856 | Evandro de Azambuja | Institut Jules Bordet | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Debien, V., Agostinetto, E., Bruzzone, M., Ceppi, M., Martins-Branco, D., Molinelli, C., Jacobs, F., Nader-Marta, G., Lambertini, M. and de Azambuja, E., 2024. The impact of initial tumor response on survival outcomes of patients with HER2-positive advanced breast cancer treated with docetaxel, trastuzumab, and pertuzumab: an exploratory analysis of the CLEOPATRA trial. Clinical Breast Cancer. Doi: 10.1016/j.clbc.2024.02.012 | Roche | 17 |
| 8052 | Wataru Fukuokaya | The Jikei University School of Medicine | Association of serum magnesium levels with effectiveness of atezolizumab in advanced urothelial carcinoma | Fukuokaya, W., Akazawa, K. and Kimura, T., 2024. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma. Anticancer Research, 44(5), pp.2117-2123. Doi: 10.21873/anticanres.17017 | Roche | 2 |
| 8180 | Sheng Luo | Duke University | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer | Li, H., Wu, Y., Zou, H., Koner, S., Plichta, J.K., Tolaney, S.M., Zhang, J., He, Y.W., Wei, Q., Tang, L. and Zhang, H., 2024. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials. EBioMedicine, 105. Doi: 10.1016/j.ebiom.2024.105186 | Daiichi Sankyo, Lilly, Pfizer, Roche | 12 |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Doyle, F. Byrne, D., Boland F. 2024. Do psychometrics matter? The effects of psychometrics on depression trial outcomes. International Meeting of the Psychomtric Society. Abstract. pg.377 | GlaxoSmithKline, Lilly, Pfizer, Takeda | N/A |
| 8266 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | The prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis | Zheng, J., Zheng, D., Fan, Z., Li, L., Chen, R. and Zhang, S., 2024. Developing and Externally Validating a Simple Index Based on the Nonlinear Relationship of Fecal Calprotectin and Long-Term Outcomes in Ulcerative Colitis. Journal of Inflammation Research, pp.11247-11256. Doi: 10.2147/JIR.S497655 | Takeda | 0 |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Almansour, S.A., Alqudah, M.A., Abuhelwa, Z., Al-Shamsi, H.O., Alhuraiji, A., Semreen, M.H., Bustanji, Y., Alzoubi, K.H., Modi, N.D., Mckinnon, R.A. and Sorich, M.J., 2024. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. Therapeutic Advances in Medical Oncology, 16, p.17588359241275387. Doi: 10.1177/17588359241275387 | Johnson & Johnson, Sanofi, Takeda | 2 |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Almansour, S.A., Alqudah, M.A., Abuhelwa, Z., Al-Shamsi, H.O., Semreen, M.H., Bustanji, Y., Soare, N.C., McKinnon, R.A., Sorich, M.J., Hopkins, A.M. and Abuhelwa, A.Y., 2024. Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials. Scientific Reports, 14(1), p.591. Doi: 10.1038/s41598-023-48640-1 | Johnson & Johnson, Sanofi, Takeda | 23 |
| 8438 | Sheng Luo | Duke University | Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time | Zhou, X., Zou, H., Lutz, M.W., Arbeev, K., Akushevich, I., Yashin, A., Welsh‐Bohmer, K.A. and Luo, S., 2024. Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 10(2), p.e12471. Doi: 10.1002/trc2.12471 | AbbVie | 10 |
| 8440 | David Seiffge | Insel Gruppe AG | Andexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC | Siepen, B.M., Polymeris, A., Shoamanesh, A., Connolly, S., Steiner, T., Poli, S., Lemmens, R., Goeldlin, M.B., Müller, M., Branca, M. and Rauch, J., 2023. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors—Individual patient data analysis of ANNEXA-4 and TICH-NOAC. International Journal of Stroke, p.17474930 241230209. Doi: 10.1177/17474930241230209 | AstraZeneca | 20 |
| 8450 | Dennis McGonagle | University of Leeds | The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients | David, P., Hen, O., Ben-Shabbat, N., Macleod, T., Amital, H., Watad, A. and McGonagle, D.G., 2024. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects. RMD open, 10(2), p.e004045. Doi: 10.1136/rmdopen-2023-004045 | Lilly | 10 |
| 8559 | Dag Aarsland | King’s College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Xue, L., Bocharova, M., Young, A.H. and Aarsland, D., 2024. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms. Journal of affective disorders. Doi: 10.1016/j.jad.2024.06.003 | Lundbeck | 6 |
| 8561 | Dale Morrison | The University of Melbourne | IMPROVING EXERCISE WITH TYPE 1 DIABETES | Morrison, D., Vogrin, S. and Zaharieva, D.P., 2024. Assessment of Glycemia Risk Index and Standard Continuous Glucose Monitoring Metrics in a Real-World Setting of Exercise in Adults With Type 1 Diabetes: A Post-Hoc Analysis of the Type 1 Diabetes and Exercise Initiative. Doi: 10.1177/19322968241246458 | Jaeb Center for Health Research Foundation, Inc. | 0 |
| 8602 | Robert Hamilton | University of Toronto | Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial | Chavarriaga, J., Lajkosz, K., Sangole, N., Penn, L.Z., Khurram, N. and Hamilton, R.J., 2024, October. Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial. In Urologic Oncology: Seminars and Original Investigations. Elsevier. Doi: 10.1016/j.urolonc.2024.08.023 | Bayer | 1 |
| 8603 | Wencai Jiang | Chengdu Second People's Hospital | Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease | Jiang, W., Huang, G., Du, J., Yang, H., Zhou, S., Dai, D., Tang, K., Fang, Y., Wang, X. and Deng, X., 2024. White blood cell counts can predict 4-year cardiovascular disease risk in patients with stable coronary heart disease: a prospective cohort study. Frontiers in Cardiovascular Medicine, 11, p.1358378. Doi: 10.3389/fcvm.2024.1358378 | GlaxoSmithKline | 1 |
| 8609 | Fredrik Schjesvold | Oslo University Hospital | Personalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. | Myklebust, E.M., Schjesvold, F., Frigessi, A., Leder, K., Foo, J. and Köhn-Luque, A., 2024. Relapse prediction in multiple myeloma patients treated with isatuximab, carfilzomib, and dexamethasone. medRxiv, pp.2024-05. Doi: 10.1101/2024.05.02.24306607 | Sanofi | 0 |
| 8611 | Adam de Havenon | Yale University | Baseline Stroke Severity in Secondary Prevention Trials | de Havenon, A., Viscoli, C., Kleindorfer, D., Sucharew, H., Delic, A., Becker, C., Robinson, D., Yaghi, S., Li, V., Lansberg, M.G. and Cramer, S.C., 2024. Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials. JAMA Network Open, 7(7), pp.e2423677-e2423677. Doi: 10.1001/jamanetworkopen.2024.23677 | Boehringer Ingelheim | 53 |
| 8686 | Andrea E. van der Meulen - de Jong | Leiden University Medical Center | Anemia and therapy with Janus Kinase Inhibitors in patients with ulcerative colitis | Loveikyte, R., Voorneveld, P.W., Dijkstra, G. and van der Meulen-de Jong, A.E., 2024. P923 Haematological abnormalities during treatment with Janus kinase inhibitors in patients with Ulcerative Colitis: a post hoc analysis. Journal of Crohn's and Colitis, 18(Supplement_1), pp.i1681-i1681. Doi: 10.1093/ecco-jcc/jjad212.1053 | Pfizer | 1 |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Klümper, N., Cox, A., Eckstein, M., Kuppe, C., Ritter, M., Brossart, P., Luetkens, J., Hölzel, M., Stein, J. and Saal, J., 2024. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. European Journal of Cancer, p.114089. Doi: 10.1016/j.ejca.2024.114089 | Roche | 6 |
| 8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Alfehaid, L.S., Farah, S., Omer, A., Weber, B.N., Alkhezi, O., Tawfik, Y.M., Shah, A.M., Libby, P. and Buckley, L.F., 2024. Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19: A Secondary Analysis of the COLCORONA Randomized Clinical Trial. JAMA Network Open, 7(9), pp.e2431309-e2431309. Doi: 10.1001/jamanetworkopen.2024.31309 | Montreal Heart Institute | 122 |
| 8764 | Giuseppe Cabibbo | University of Palermo | Competing risk factors in survival analyses for advanced hepatocellular carcinoma outcomes. The key role of liver function and impact of drug class | Cabibbo, G., Celsa, C., Battaglia, S., Enea, M., Di Maria, G., Grova, A., Ciccia, R., Manfredi, G.F., Iavarone, M., Vogel, A. and Singal, A.G., 2024. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Clinical Cancer Research. Doi: 10.1158/1078-0432.CCR-24-2582 | Roche | 41 |
| 8837 | Erin Tallon | Children's Mercy Kansas City | Development of an mHealth-Based Just-In-Time Adaptive Intervention (JITAI) for Promoting Physical Activity in Individuals with Type 1 Diabetes | Panfil K, Tallon EM, Lockee B, Williams DD, Patton SR, Clements M. Impact of moderate-to-vigorous physical activity on continuous glucose monitor-derived metrics in youth with type 1 diabetes. Diabetes Technol Ther 2024; 26(S2):EV257. Doi: 10.1089/dia.2024.2525.abstracts | Jaeb Center for Health Research Foundation, Inc. | 9 |
| 8926 | Alessio Cortellini | Imperial College London | The putative differential impact of opioids exposure in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy or chemotherapy: a post-hoc analysis of the randomized phase 2 POPLAR and phase 3 OAK trials. | Cortellini A., Santo V., Brunetti L., Mangani D., Anderson A.C., Vincenzi B., Tonini G., Takada K., Naqash A.R., Ricciuti B., Pinato D.J. Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials. JCO 42, 2607-2607(2024). Doi: 10.1200/JCO.2024.42.16_suppl.2607 | Roche | 4 |
| 8933 | Joao Pedro Ferreira | University of Porto | Non cardiovascular hospitalizations in heart failure and preserved ejection fraction (HFpEF) and the effect of empagliflozin | Ferreira, J.P., Zannad, F., Packer, M., Filippatos, G., Pocock, S.J., Vasques‐Nóvoa, F., Böhm, M., Butler, J. and Anker, S., 2024. Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis. European Journal of Heart Failure. Doi: 10.1002/ejhf.3180 | Boehringer Ingelheim | 3 |
| 8957 | Dean Bodenham | Imperial College London | Two-sample testing for clinical trials data with missing values | Zeng Y., Adams N.M., Bodenham D.A. 2024. On two-sample testing for data with arbitrarily missing values. arXiv preprint. Doi: 10.48550/arXiv.2403.15327 | Bayer | 1 |
| 9103 | JOSE GARCIA-TIRADO | University of Bern | Automatic Recognition of Main Glycemic Disturbances in Type 1 Diabetes (T1D) | CYPRIS, L.E. and GARCIA-TIRADO, J.F., 2024. 243-OR: Characterization of Behavioral Patterns Involving Hypoglycemic Episodes in Type 1 Diabetes—Results from the T1DEXI Study Cohort. Diabetes, 73(Supplement_1). Doi : 10.2337/db24-243-OR | Jaeb Center for Health Research Foundation, Inc. | N/A |
| 9137 | Ly-Mee Yu | University of Oxford | Loop Diuretics and Weight Change in Heart Failure A Meta-Analysis | Phan, Y., 2024. Meta-Analysis on Aggregate Data and Individual Patient Data Using R. Phuse EU Connect. Abstract PP06. | Bayer, Boehringer Ingelheim, GlaxoSmithKline | N/A |
| 9241 | Amit Garg | Northwell Health | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | Midgette, B., Strunk, A. and Garg, A., 2024. Association between skin-related quality of life and race in patients with moderate-to-severe hidradenitis suppurativa: Analysis of two phase 3 clinical trials. Journal of the American Academy of Dermatology. Doi: 10.1016/j.jaad.2024.07.1508 | AbbVie | 2 |
| 9241 | Amit Garg | Northwell Health | Association between skin-related quality of life and race in patients with hidradenitis suppurativa, and Repeatability/Intra-rater agreement of lesion counts in hidradenitis suppurativa | Midgette B, Strunk A, Garg A. Association Between Skin-Related Quality of Life and Race in Patients with Hidradenitis Suppurativa. Annual Meeting of the Medical Dermatology Society. Poster. 2024. | AbbVie | N/A |
| 9244 | Kazuki Takada | Saiseikai Fukuoka General Hospital, Fukuoka, Japan | Impact of Probiotics on Clinical Outcomes in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Atezolizumab Combination Therapy A Post Hoc Analysis of IMpower133 | Takada, K., Takamori, S., Shimokawa, M., Pinato, D.J. and Cortellini, A., Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial. International journal of cancer. Doi: 10.1002/ijc.35249 | Roche | 1 |
| 9286 | Joao Sergio Neves | Faculdade de Medicina da Universidade do Porto | Effect of Exenatide Across the Spectrum of Ejection Fraction: An analysis from the EXSCEL trial | Neves, J.S., Leite, A.R., Mentz, R.J., Holman, R.R., Zannad, F., Butler, J., Packer, M. and Ferreira, J.P., 2024. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial. European Journal of Heart Failure. Doi: 10.1002/ejhf.3478 | AstraZeneca | 16 |
| 9332 | Neeraj Narula | Hamilton Health Sciences | Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease | Samnani, S., Wong, E.C., Hamam, H., Dulai, P.S., Marshall, J.K., Jairath, V., Reinisch, W. and Narula, N., 2024. Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease. Journal of Crohn's and Colitis, p.jjae151. Doi: 10.1093/ecco-jcc/jjae151 | Johnson & Johnson, Takeda | 0 |
| 9383 | Joao Pedro Ferreira | Faculty of Medicine of Porto University | Anemia and the Effect of Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF) findings from EMPEROR-Preserved | Ferreira, J.P., Zannad, F., Vasques-Nóvoa, F., Neves, J.S., Filippatos, G., Pocock, S.J., Butler, J., Packer, M. and Anker, S.D., 2024. Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Heart Journal, p.ehae864. Doi: 10.1093/eurheartj/ehae864 | Boehringer Ingelheim | 0 |
| 9492, 8697 | David McAllister | University of Glasgow | Understanding frailty, multimorbidity and renal failure in clinical trials Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions | Hanlon, P., Butterly, E., Wei, L., Wightman, H., Almazam, S.A.M., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K. and Lewsey, J., 2024. Age-and sex-differences in efficacy of treatments for type 2 diabetes: Network meta-analysis of aggregate and individual level data. medRxiv, pp.2024-06. Doi: 10.1101/2024.06.23.24309242 | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB | 0 |
| 10039, 8807 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Liu H., Ray T., Friberg LE. Comparison between multistate and parametric time-to-event models for analysis of progression-free-survival (PFS) and overall survival (OS) in oncology trials. 2024. Population Approach Group People, PAGE 32. Abstract 10980. | Pfizer | N/A |
| 10118 | Neeraj Narula | Hamilton Health Sciences | Assessing Outcomes from the EXTEND Clinical Trial Using the Modified Multiplier of the Simple Endoscopic Score for Crohn's disease (MM-SES-CD) | Wong, E.C., Dulai, P.S., Marshall, J.K., Laroux, S., Jairath, V., Reinisch, W. and Narula, N., 2024. Use of Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial. Journal of Crohn's and Colitis, p.jjae171. Doi: 10.1093/ecco-jcc/jjae171 | AbbVie | 1 |
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetrics Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3876 | Changyu Shen | Beth Israel Deaconess Medical Center | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Aggarwal R, Ruff C T, Virdone S, Perreault S, Kakkar A K, Palazzolo M G, Dorais M, Kayani G, Singer D E, Secemsky E, Piccini J, Tahir U A, Shen C, 7 Yeh R W. (2023). Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation. Doi: 10.1161/CIRCULATIONAHA.123.064556 | Boehringer Ingelheim, Daiichi Sankyo | 129 | 11 |
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):183-192. doi : 10.2215/CJN.0000000000000050 | GlaxoSmithKline, Takeda | 11 | 3 |
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J. and Goicoechea, M., 2023. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, pp.1-10. Doi: 10.1038/s41591-023-02418-0 | GlaxoSmithKline, Takeda | 59 | 22 |
| 4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center | Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trials | Vogel LH, Dykun I, Raggi P, Schmermund A, Rassaf T, Mahabadi AA. High- vs. Low-Intensity Statin Therapy and Changes in Coronary Artery Calcification Density after One Year. Journal of Clinical Medicine. 2023; 12(2):476. doi: https://doi.org/10.3390/jcm12020476 | Pfizer | 3 | 3 |
| 4120 | Merryn Voysey | University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Feng, S., McLellan, J., Pidduck, N., Roberts, N., Higgins, J.P., Choi, Y., Izu, A., Jit, M., Madhi, S.A., Mulholland, K. and Pollard, A.J., 2023. Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data. EClinicalMedicine, 61. doi: 10.1016/j.eclinm.2023.102073 | Pfizer | 2 | 0 |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Takase-Minegishi K, Böhringer S, Nam J, et al. POS0181 THE IMPACT OF AUTOANTIBODIES (RF AND ACPA) ON THE EFFICACY OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Annals of the Rheumatic Diseases 2023;82:315-31 6. | AbbVie, Pfizer | 0 | N/A |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V., Ravindranath, V., Arneson, D., Mosenia, A., Butte, A. and Wang, S., 2023. S936 Optimizing Treatment Selection in Crohn’s Disease Using Patient-Specific Features: An Individual Participant Data Meta-Analysis of Fifteen Randomized Controlled Trials. Official journal of the American College of Gastroenterology| ACG, 118(10S), pp.S701-S702. Doi: 10.14309/01.ajg.0000953384.20574.a3 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 0 | 1 |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V.A., Ravindranath, V.G., Arneson, D.V., Mosenia, A., Butte, A.J. and Wang, S., 2023. Sequential regression and simulation: a method for estimating causal effects from heterogeneous clinical trials without a common control group. BMC Medical Research Methodology, 23(1), pp.1-12. Doi: 10.1186/s12874-023-02020-5 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 0 | 0 |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | Rudrapatna, V.A., Ravindranath, V., Arneson, D.V., Mosenia, A., Butte, A.J. and Wang, S., 2023. Personalizing treatment selection in Crohn's disease: a meta-analysis of individual participant data from fifteen randomized controlled trials. medRxiv, pp.2023-11. Doi: 10.1101/2023.11.10.23291837 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 0 | N/A |
| 5080 | Joel Skaistis | Beaumont Health | Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker Level | J. Skaistis, J. George, H.C. Diener. Dabigatran Treatment in Embolic Stroke of Undetermined Source and Elevated Biomarkers: the RE-SPECT ESUS Trial. CJC Open (2023). doi : 10.1016/j.cjco.2022.12.013 | Boehringer Ingelheim | 0 | N/A |
| 5209 | Bruce Perkins | University of Toronto | TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL | Song, C., Dhaliwal, S., Bapat, P., Scarr, D., Bakhsh, A., Budram, D., Verhoeff, N.J., Weisman, A., Fralick, M., Ivers, N.M. and Cherney, D.Z., 2023. Point-of-care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care. Doi: 10.2337/dc23-0840 | Boehringer Ingelheim | 0 | 1 |
| 5276 | Yan Luo | Kyoto University | Predicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | Luo, Y., Chalkou, K., Funada, S., Salanti, G. and Furukawa, T.A., 2023. Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis. JAMA Network Open, 6(6), pp.e2321398-e2321398. doi:10.1001/jamanetworkopen.2023.21398 | UCB | 14 | 0 |
| 5294 | Daniel Caldeira | University of Lisbon/CCUL | The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY | Caldeira, D., Alves da Silva, P. and Pinto, F.J., 2023. Clinical outcomes of anticoagulated patients with atrial fibrillation after falls or head injury: insights from RE-LY. Stroke. 2023;54:1656–1659. doi : 10.1161/STROKEAHA.122.041628 | Boehringer Ingelheim | 3 | 1 |
| 5327, 5985 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Ferreira RJO, Welsing PMJ, Jacobs JWG, et al. Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. Ann Rheum Dis 2021;80:293–303. doi :10.1136/annrheumdis-2020-217171 | AbbVie, Pfizer, Roche, UCB | https://www.altmetric.com/details/91927204?src=bookmarklet | https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed_citedin&from_uid=33023964 |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Belfiore-Oshan, R., Aggarwal, V., Wilk, J., Pauley, M., Corey, D., Romero, K., Hovinga, C., Martinez, T., Lingineni, K., Yoon, D., Kim, S. and Morales, J., 2023. P146 A clinical trial simulation tool to accelerate trial design in DMD: description of the traphical user interface features and applications. Neuromuscular Disorders, 33, p.S84. Doi: 10.1016/j.nmd.2023.07.081 | CureDuchenne | 0 | N/A |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Jennifer Lees. The impact of age, sex, comorbidity count and race/ethnicity on attrition and screen failure from trials. Kidney Health Symposium 2023, Event held on 24th Feb 2023. (From 34-58 mins) https://ctc.usyd.edu.au/news-events/kidney-health-symposium-2023/ | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB | N/A | N/A |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Lees, J.S., Crowther, J., Hanlon, P., Butterly, E., Wild, S., Mair, F.S., Guthrie, B., Gillies, K., Dias, S., Welton, N.J. and Katikireddi, S.V., 2023. Participant characteristics and exclusion from trials: a meta-analysis of individual participant-level data from phase 3/4 industry-funded trials in chronic medical conditions. medRxiv, pp.2023-04. Doi: 10.1101/2023.04.14.23288549 | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB | 0 | N/A |
| 5852 | Marliese Alexander | Peter MacCallum Cancer Centre | Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis | Alexander M, Jachno K, Phillips KA, Seymour JF, Slavin MA, Cheung A, Shen V, Maarouf D, Wolfe R, Lingaratnam S. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis. Journal of Oncology Pharmacy Practice. 2023 Jun 16. doi : 10.1177/10781552231180875 | Roche | 0 | 0 |
| 5924 | Iris Sommer | University Medical Center Groningen | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies | d’Angremont E, Begemann MJH, van Laar T, Sommer IEC. Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis. JAMA Neurol. Published online June 26, 2023. doi:10.1001/jamaneurol.2023.1835 | AbbVie, GlaxoSmithKline, Johnson & Johnson | 81 | 6 |
| 5925 | Min Hwan Kim | Yonsei University College of Medicine | Analysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical response | Kim, C.G., Kim, M.H., Kim, J.H. et al. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates. Breast Cancer Res 25, 4 (2023). doi : 10.1186/s13058-022-01601-4 | Pfizer | 0 | 6 |
| 5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Shin, H., Wang, S.V., Kim, D.H., Alt, E., Mahesri, M., Bessette, L.G., Schneeweiss, S. and Najafzadeh, M. Predicting treatment effects of a newâ€toâ€market drug in clinical practice based on phase III randomized trial results. Clinical Pharmacology & Therapeutics. Doi: 10.1002/cpt.2983 | Boehringer Ingelheim | 1 | 1 |
| 5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Shin, H., Wang, S., Kim, D.H., Alt, E., Mahesri, M., Bessette, L.G., Schneeweiss, S. and NajafZadeh, M., 2023. MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results. Value in Health, 26(6), p.S285. Doi: 10.1016/j.jval.2023.03.1576 | Boehringer Ingelheim | 0 | N/A |
| 5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | Maria A de Winter, Harry R Büller, Marc Carrier, Alexander T Cohen, John-Bjarne Hansen, Karin A H Kaasjager, Ajay K Kakkar, Saskia Middeldorp, Gary E Raskob, Henrik T Sørensen, Frank L J Visseren, Philip S Wells, Jannick A N Dorresteijn, Mathilde Nijkeuter, VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. European Heart Journal, 2023;. ehac776. doi: 10.1093/eurheartj/ehac776 | Boehringer Ingelheim, Daiichi Sankyo | 148 | 10 |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | Duarte, C., Ferreira, R.J.O., Welsing, P., Jacobs, J.W.G., Gossec, L., Machado, P., Van der Heijde, D. and Da Silva, J.A.P., 2023. OP0189 REMISSION CRITERIA GUIDING IMMUNOSUPPRESSIVE THERAPY IN RA: WHICH IS BEST FITTED FOR THIS PURPOSE?. Doi: 10.1136/annrheumdis-2023-eular.1853 | AbbVie, Pfizer, Roche, UCB | 0 | N/A |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors. | Espinoza, M., Muiquith, M., Lim, M., Zhu, H., Singal, A. G., & Hsiehchen, D. (2023). Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: Post-hoc analysis of IMbrave150. Gastroenterology. doi : 10.1053/j.gastro.2023.02.042 | Roche | N/A | 21 |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors. | Lim, M., Muquith, M., Miramontes, B., Lee, C.J., Espinoza, M., Huang, Y.H. and Hsiehchen, D., 2023. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. Hepatology, pp.10-1097. Doi: 10.1097/HEP.0000000000000494 | Roche | 3 | 3 |
| 6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Dubbelman, M.A., Vromen, E.M., Tijms, B.M., Ottenhoff, L., Vijverberg, E.G., Prins, N.D., van der Flier, W.M. and Sikkes, S.A., 2023, July. P1-743 - Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach. In Alzheimer's Association International Conference. ALZ. | Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly | N/A | N/A |
| 6104 | Pratik Sinha | Washington University | Heterogeneous treatment effects in molecular phenotypes of sepsis | Sinha, P., Kerchberger, V.E., Willmore, A., Chambers, J., Zhuo, H., Abbott, J., Jones, C., Wickersham, N., Wu, N., Neyton, L. and Langelier, C.R., 2023. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. The Lancet Respiratory Medicine. Doi:10.1016/S2213-2600(23)00237-0 | Lilly | 27 | 29 |
| 6475 | Tobias Polak | Erasmus Medical Center | Combining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib | Polak, T.B., Labrecque, J.A., Groot, C.A. and van Rosmalen, J., 2023. Augmenting treatment arms with external data through propensity-score weighted power-priors: an application in expanded access. arXiv preprint. doi: arXiv:2306.01557. | Roche | 0 | N/A |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | Yousefi, E., Gewily, M., König, F., Höglinger, G., Hopfner, F., Karlsson, M.O., Ristl, R., Zehetmayer, S. and Posch, M., 2023. Efficiency of Multivariate Tests in Trials in Progressive Supranuclear Palsy. arXiv preprint arXiv:2312.08169. Doi: 10.48550/arXiv.2312.08169 | AbbVie | https://www.altmetric.com/details/163974029?src=bookmarklet1 | N/A |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | Modi, N., Abuhelwa, A.Y., Rowland, A., Menz, B.D., McKinnon, R.A., Sorich, M.J. and Hopkins, A.M., 2023. Association between patient-reported outcomes and therapeutic outcomes in patients with breast cancer: A pooled individual-participant data analysis. Doi: 10.1200/JCO.2023.41.16_suppl.530 | Lilly, Roche, Pfizer | 0 | N/A |
| 6521 | Ethan Alt | University of North Carolina at Chapel Hill | Bayesian probability of success for multivariate generalized linear models | Alt, E. M., Psioda, M. A., & Ibrahim, J. G. (2023). A Bayesian approach to study design and analysis with type I error rate control for response variables of mixed types. Statistics in Medicine. doi: 10.1002/sim.9696 | Biogen | 4 | 0 |
| 6544 | Angela Wu | University of Oxford | Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders | Wu, A.D., Gao, M., Aveyard, P. and Taylor, G., 2023. Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders. JAMA Network Open, 6(5), pp.e2316111-e2316111. Doi: 10.1001/jamanetworkopen.2023.16111 | Pfizer | 448 | 6 |
| 6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | James R Brorson, Shyam Prabhakaran, S Claiborne Johnston, Mihai Giurcanu. Abstract WMP61: Vulnerable And Stabilized States After Cerebral Ischemic Events: Implications Of Kinetic Modeling In The POINT, SOCRATES, And THALES Trials. Stroke. 2023;54:AWMP61. doi: 10.1161/str.54.suppl_1.WMP61 | AstraZeneca | 1 | N/A |
| 6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | Brorson, J.R., Giurcanu, M., Prabhakaran, S. and Johnston, S.C., 2023. Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology. Doi: 10.1212/WNL.0000000000207904 | AstraZeneca | 0 | 0 |
| 6594 | Manju Subramanian | Boston Medical Center | The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis | Nayan Sanjiv, Pawarissara Osathanugrah, Steven Ness, Xuejing Chen, Nicole Siegel, Manju L Subramanian. Impact of Race on Treatment of Ranibizumab in Diabetic Macular Edema: A Pooled Analysis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2713. | Roche | N/A | N/A |
| 6642 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohns Disease | C Galts, N Narula, E Wong, W Reinisch. A116 OPTIMIZING CROHN’S DISEASE ENDOSCOPIC SCORING OPERATING CHARACTERISTICS TO ASSIST WITH THE ADVENT OF ARTIFICIAL INTELLIGENCE. Journal of the Canadian Association of Gastroenterology, Volume 6, Issue Supplement_1, March 2023, Page 63. doi: 10.1093/jcag/gwac036.116 | AbbVie | 1 | N/A |
| 6712 | Yeon-Mok Oh | Asan Medical Center | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | Lee JH, Kim S, Oh YM. A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2023;18:113-127. doi : 10.2147/COPD.S389502 | GlaxoSmithKline | 9 | 1 |
| 6712 | Yeon-Mok Oh | Asan Medical Center | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | Jang Ho Lee, Sehee Kim, Yeon-Mok Oh. Development of a scoring model for the prediction of the effects of discontinuation or addition of inhaled corticosteroid in chronic obstructive pulmonary disease patients. Volume 28, Issue S1 Supplement: 26th Congress of the Asian Pacific Society of Respirology Above and Beyond, 17–20 November 2022, Seoul, Korea, February 2023, P45-46 AO07-3. doi: 10.1111/resp.14433#14433-sec-0269 | GlaxoSmithKline | 1 | 0 |
| 6716 | Nigam Shah | Stanford University | Applying machine learning tools to personalize dabigatran treatment decisions | Xu, Y., Bechler, K., Callahan, A., & Shah, N. (2023). Principled estimation and evaluation of treatment effect heterogeneity: A case study application to dabigatran for patients with atrial fibrillation. Journal of Biomedical Informatics, 104420. doi :10.1016/j.jbi.2023.104420 | Boehringer Ingelheim | 0 | 2 |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Huang Yongquan (2023). Risk Evaluation for Ischemic Stroke Patients with Non-Valvular Arrythmia by Using Integrated Multistage Machine Learning Predictive Scheme. (PhD thesis. Fu Jen Catholic University). National Digital Libraries of Theses and Dissertations in Taiwan. https://hdl.handle.net/11296/zy9jzs | Boehringer Ingelheim | N/A | N/A |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Huang Y-C, Cheng Y-C, Jhou M-J, Chen M, Lu C-J. Integrated Machine Learning Decision Tree Model for Risk Evaluation in Patients with Non-Valvular Atrial Fibrillation When Taking Different Doses of Dabigatran. International Journal of Environmental Research and Public Health. 2023; 20(3):2359. doi: 10.3390/ijerph20032359 | Boehringer Ingelheim | 1 | 0 |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Xiao, Z., Ding, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., Feng, J., Wang, G., Tang, J. and Can, J., 2023. 9P Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. ESMO Open, 8(1). Doi: 10.1016/j.esmoop.2023.101233 | Roche | 0 | N/A |
| 6764 | Camila Olarte Parra | London School of Hygiene and Tropical Medicine | Hypothetical estimand in clinical trials: an application of causal inference and missing data methods | Olarte Parra, C., Daniel, R.M., Wright, D. and Bartlett, J.W., 2023. Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial. arXiv e-prints, pp.arXiv-2308. Doi: 10.48550/arXiv.2308.13085 | AstraZeneca | N/A | N/A |
| 6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Rojewski AM, Palmer AM, Baker NL, Toll BA. Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial. Nicotine and Tobacco Research. 2023 Jul 20:ntad126. doi: 10.1093/ntr/ntad126 | Pfizer | 0 | 1 |
| 6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Rojewski A, Palmer AM, Baker NL, Toll, BA. SMOKING CESSATION PHARMACOTHERAPY EFFICACY IN COMORBID MEDICAL POPULATIONS: SECONDARY ANALYSIS OF THE EAGLES RANDOMIZED CLINICAL TRIAL. The Society for Research on Nicotine & Tobacco. POS1-12. 2023. | Pfizer | N/A | N/A |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Giulio Francesco Romiti, Marco Proietti, Niccolò Bonini, Wern Yew Ding, Giuseppe Boriani, Menno V. Huisman, Gregory Y.H. Lip. Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry. eClinicalMedicine, Volume 55, 2023, 101757. doi: 10.1016/j.eclinm.2022.101757 | Boehringer Ingelheim | 8 | 25 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica B, Romiti GF, Proietti M, Mei DA, Boriani G, Chao TF, Olshansky B, Huisman MV, Lip GY, GLORIA-AF Investigators. Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry. InMayo Clinic Proceedings 2023 Aug 25. doi : 10.1016/j.mayocp.2023.07.013 | Boehringer Ingelheim | 9 | 0 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti GF, Corica B, Proietti M, Mei DA, Frydenlund J, Bisson A, Boriani G, Olshansky B, Chan YH, Huisman MV, Chao TF. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry. eClinicalMedicine. 2023 Aug 25. doi : 10.1016/j.eclinm.2023.102039 | Boehringer Ingelheim | 5 | 4 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a Risk Factor for Atrial Fibrillation-Related Stroke. Thromb Haemost. 2023 Oct 23. doi: 10.1055/s-0043-1776394 | Boehringer Ingelheim | 13 | 5 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti GF, Proietti M, Corica B, Bonini N, Boriani G, Huisman MV, Lip GYH; GLORIAâ€AF Investigators. Implications of Clinical Risk Phenotypes on the Management and Natural History of Atrial Fibrillation: A Report From the GLORIA-AF. J Am Heart Assoc. 2023 Oct 17;12(20):e030565. doi : 10.1161/JAHA.123.030565 | Boehringer Ingelheim | 17 | 3 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Corica, B., Romiti, G.F., Proietti, M., Mei, D.A., Boriani, G., Chao, T.F., Olshansky, B., Huisman, M.V. and Lip, G.Y.H., 2023. Adverse outcomes according to metabolic status in obese and overweight patients with atrial fibrillation: a report from the GLORIA-AF Phase II and III Registry. European Heart Journal, 44(Supplement_2), pp.ehad655-432. Doi: 10.1093/eurheartj/ehad655.432 | Boehringer Ingelheim | 0 | N/A |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti, G.F., Corica, B., Proietti, M., Mei, D.A., Frydenlund, J., Bisson, A., Boriani, G., Olshansky, B., Chan, Y.H., Huisman, M.V. and Chao, T.F., 2023. Oral anticoagulant use and outcomes in Asian patients with atrial fibrillation in the GLORIA-AF Registry. European Heart Journal, 44(Supplement_2), pp.ehad655-433. Doi: 10.1093/eurheartj/ehad655.433 | Boehringer Ingelheim | 1 | N/A |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti, G.F., Proietti, M., Corica, B., Mei, D.A., Frost, F., Bisson, A., Boriani, G., Olshansky, B., Chao, T.F., Huisman, M.V. and Lip, G.Y.H., 2023. Impact of chronic obstructive pulmonary disease on the natural history of atrial fibrillation: a report from the GLORIA-AF registry phase II & III. European Heart Journal, 44(Supplement_2), pp.ehad655-573. Doi: 10.1093/eurheartj/ehad655.573 | Boehringer Ingelheim | 2 | N/A |
| 7078 | Alberto Martini | San Raffaele University | Role of body mass index and Beta Blockers in metastatic urothelial carcinoma | Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Necchi A, Martini A. PD09-11 THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMvigor210 AND IMvigor211. The Journal of Urology. 2023 Apr;209(Supplement 4):page e244. doi: 10.1097/JU.0000000000003240.11 | Roche | 8 | N/A |
| 7078 | Alberto Martini | San Raffaele University | Role of body mass index and Beta Blockers in metastatic urothelial carcinoma | Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. The immuneâ€related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials. BJU international. doi: 10.1111/bju.16121 | Roche | 14 | 1 |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | Gunter S, Porter M, Gibson R, Kimball AB. 423 Baseline C-reactive protein correlates with adalimumab and placebo 3non-response in patients with hidradenitis suppurativa. Journal of Investigative Dermatology. 2023 May 1;143(5):S73. https://www.jidonline.org/article/S0022-202X(23)00604-8/pdf | AbbVie | N/A | N/A |
| 7142 | Sara Tedeschi | Brigham and Women’s Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Tedeschi S, Hayashi K, Zhang Y, Choi H, Solomon D. Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). | Takeda | N/A | N/A |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | McDonald CM, Marden JR, Shieh PB, et al. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status. Journal of Comparative Effectiveness Research. 2023 Feb:e220190. doi : 10.57264/cer-2022-0190. | CureDuchenne | N/A | 1 |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | Kerr W, Kok N, Reddy A, Stacey W, Stern J, Pennell P, French J. Time to event trial endpoints best measured efficacy when seizure counting started during maintenance excluding titration.American Epilepsy Society Annual Meeting. [See Abstracts tab]. Poster 1.285. 2023 | GlaxoSmithKline, Johnson & Johnson, UCB | N/A | N/A |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | Kerr W, Kok N, Reddy A, Stacey W, Stern J, Pennell P, French J. Time to prerandomization seizure count demonstrated efficacy of levetiracetam, lacosamide, lamotrigine, and brivaracetam with less placebo exposure. American Epilepsy Society Annual Meeting. [See Abstracts tab]. Poster 1.287. 2023 | GlaxoSmithKline, Johnson & Johnson, UCB | N/A | N/A |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | M. Roulleaux Dugage, M. Tagliamento, T. Gorria, A. Rochand, L. Garcin, S. Oudard, C. Thibault, V.M. Albarran Artahona, J.C. Laguna Montes, I. Nalda Ariza, F.J. Muñoz i Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixido, B. Besse, L. Mezquita, E. Auclin. 1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases. Annals of Oncology (2023) 34 (suppl_2): S755-S851. doi : 10.1016/annonc/annonc1331 | Project Data Sphere, Roche | N/A | N/A |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | M. Roulleaux Dugage, T. Gorria, A. Rochand, L-M. Garcin, S. Oudard, V. Albarrán-Artahona, J.C. Laguna, I. Nalda, F.J. Muñoz-Carrillo, L. Aguilar, A. Arcocha, L. Lupinacci, C. Teixidó, B. Besse, L. Mezquita, E. Auclin. Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC. World Conference on Lung Cancer. (2023). | Project Data Sphere, Roche | N/A | N/A |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | J. Saal, T. Bald, M. Eckstein, D.J. Ralser, M. Ritter, P. Brossart, V. Grünwald, M. Hölzel, J. Ellinger, N. Klümper. A0332 - On-treatment modified Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma, European Urology, Volume 83, Supplement 1, 2023, Page S483,ISSN 0302-2838. doi: 10.1016/S0302-2838(23)00381-0 | Roche | 1 | N/A |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klümper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology. doi: 10.1001/jamaoncol.2023.1822 | Roche | 142 | 7 |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal J, Bald T, Eckstein M, Ralser D, Ritter M, Brossart P, Grünwald V, Hölzel M, Ellinger J, Klümper N. (2023). In the phase 2/3 IMmotion150/151 study, the Modified Glasgow Prognostic Score (mGPS) improves the imaging-only prediction of treatment response in patients with metastatic renal cell carcinoma. North Rhine-Westphalian Society for Urology. Doi : 10.3205/23nrwgu20 | Roche | N/A | N/A |
| 7224 | Keiichi Fujiwara | Gynecologic Oncology Trial and Investigation Consortium (GOTIC) | Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technology | Miyagi, Y., Keiichi Fujiwara, Hisanaga Nomura, Koji Yamamoto, & Robert L Coleman. (2023). Feasibility of New Method for the Prediction of Clinical Trial Results Using Compressive Sensing of Artificial Intelligence. British Journal of Healthcare and Medical Research, 10(1), 237–267. doi : 10.14738/bjhmr.101.14061 | Boehringer Ingelheim, Lilly, Roche | 2 | N/A |
| 7232 | Neil Oxtoby | University College London | Identification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling | C. Shand, N.P. Oxtoby. INVESTIGATING TREATMENT EFFECT HETEROGENEITY IN DATA-DRIVEN SUBGROUPS OF TOMMORROW. Journal of Prevention of Alzheimer’s Disease. 2023; Abstract P004, pg. S57 | Takeda | N/A | N/A |
| 7321 | Neeraj Narula | Hamilton Health Sciences | A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis | Wong ECL, Merat S, Monaco C, Dulai PS, Jairath V, Marshall JK, Reinisch W, Narula N. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study. Dig Dis Sci. 2023 Jun;68(6):2635-2646. doi : 10.1007/s10620-023-07956-8 | Johnson & Johnson, Pfizer | 7 | 0 |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Guo, T., Zhou, Y., Liang, F., Wang, Z., Bourbonne, V., Käsmann, L., Sundahl, N., Wu, A.J.C., Ni, J. and Zhu, Z., 2024. Association of previously irradiated stable brain metastases with outcomes of atezolizumabâ€treated nonâ€small cell lung cancer: A pooled analysis of individual patient data from three randomized trials. Cancer Communications, 44(2), p.278. Doi: 10.1002/cac2.12512 | Roche | 2 | 0 |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Zhou, Y., Ni, J., Zhu, Z. and Zhang, Z., 2023. Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment. Doi: 10.1200/JCO.2023.41.16_suppl.2032 | Roche | 0 | N/A |
| 7394, 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Manning-Bennett AT, Cervesi J, Bandinelli P-A, Sorich MJ, Hopkins AM. Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. Biomedicines. 2023; 11(2):528. doi : 10.3390/biomedicines11020528 | Roche | 1 | N/A |
| 7394, 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Lee X Li, Federico Cappuzzo, Ignacio Matos, Mark A Socinski, Ashley M Hopkins, Michael J Sorich. Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. The Oncologist, 2023;, oyad043. doi: 10.1093/oncolo/oyad043 | Roche | 19 | 5 |
| 7399 | Yoichi Naito | National Cancer Center Hospital East | Correlation of doxorubicin dose and survival in patients with soft tissue sarcoma; Data from two studies (a larger phase III study and a smaller phase II study) will be combined and analyzed. | Naito, Y., Sakamaki, K., Morita, S., Mukohara, T. and Akimoto, T., 2023. 1923P Combined analysis of phase III ANNOUNCE study and phase II study exploring olaratumab in advanced soft tissue sarcoma. Annals of Oncology, 34, pp.S1034-S1035. Doi: 10.1016/j.annonc.2023.09.1152 | Lilly | 0 | N/A |
| 7520 | Malathi Ram | Johns Hopkins University | ACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis | Di Stefano, L., Ram, M., Scharfstein, D. O., Li, T., Khanal, P., Baksh, S. N., ... & Freilich, D. A. (2023). Losartan in hospitalized patients with COVID-19 in North America: An individual participant data meta-analysis. Medicine, 102(23). Doi: 10.1097/MD.0000000000033904 | Bassett Medical Center, Sharp Healthcare, University of Kansas Medical Center, University of Minnesota | 2 | 2 |
| 7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | Narula, N., Wong, E.C.L., Dulai, P.S. et al. Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission. Dig Dis Sci (2023). doi:  10.1007/s10620-023-07825-4 | AbbVie, Takeda | 1 | 0 |
| 7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | Wong, E.C., Dulai, P.S., Marshall, J.K., Jairath, V., Reinisch, W. and Narula, N., 2023. Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy. Inflammatory Bowel Diseases, p.izad077. doi: 10.1093/ibd/izad077 | AbbVie, Takeda | 0 | 0 |
| 7544 | Abhimanyu Mahajan | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | Abhimanyu M, Gonzalez D A, Stebbins G T & Comella C. 2023. Therapeutic benefit of sensory trick in cervical dystonia. Movement Disorders Clinical Practice. Doi: 10.1002/mdc3.13874 | AbbVie | 11 | 0 |
| 7544 | Abhimanyu Mahajan | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | A. Mahajan, D. Gonzalez, G. Stebbins, C. Comella. Quantifying the impact of sensory tricks on the overall severity of cervical dystonia [abstract]. Mov Disord. 2023; 38 (suppl 1) | AbbVie | N/A | N/A |
| 7581 | Rustam Al-Shahi Salman | University of Edinburgh | Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) | Al-Shahi Salman R, Stephen J, Tierney JF, Lewis SC, Newby DE, Parry-Jones AR, White PM, Connolly SJ, Benavente OR, Dowlatshahi D, Cordonnier C, Viscoli CM, Sheth KN, Kamel H, Veltkamp R, Larsen KT, Hofmeijer J , Kerkhoff H, Schreuder FHBM, Shoamanesh A, Klijn CJM, Van der Worp HB. 2023. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology. doi: 10.1016/S1474-4422(23)00315-0 | Daiichi Sankyo | 56 | 4 |
| 7583, 5932 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients | Saifi O, Bachir B, Panoff J, Poortmans P, Zeidan YH. Post-mastectomy Radiation Therapy in HER-2 Positive Breast Cancer after Primary Systemic Therapy: Pooled Analysis of TRYPHAENA and NeoSphere Trials. Radiother Oncol. 2023 Apr 6:109668. doi : 10.1016/j.radonc.2023.109668 | Roche | 57 | 0 |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sudhir Sivakumaran, Yashmin Karten, Nicholas Cullen, Corissa Lau, Eileen Priest, Hazel White, Klaus Romero, Michael Irizarry. Accelerating drug development through precompetitive data sharing and collaboration in the Critical Path for Alzheimer’s Disease (CPAD) Consortium. Abstract P0325/#231, p325. | Lilly | N/A | N/A |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran, S., Cui, Z., Priest, E., Lau, C., White, H., Irizarry, M.C., Romero, K. and Karten, Y., 2022. Development of Clinical Trial Simulation Tools for Alzheimer’s Disease through the Critical Path for Alzheimer’s Disease (CPAD) Consortium. Alzheimer's Association International Conference. P4-642. | Lilly | N/A | N/A |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran S, Cullen N, Lau C, Priest E, White H, Irizarry M, Klein G, Romero K, Leuzy A, Karten Y. , 2023. PLANNING THE NEXT GENERATION OF ALZHEIMER’S DISEASE CLINICAL TRIALS USING DIVERSE PATIENT-LEVEL DATABASE FROM THE CRITICAL PATH FOR ALZHEIMER’S DISEASE (CPAD) CONSORTIUM. 16th Clinical Trials on Alzheimer’s Disease (CTAD) Boston, MA (USA) October 24-27, 2023. PO32. S84. Posters. J Prev Alzheimers Dis 10 (Suppl 1). Doi: 10.14283/jpad.2022.130 | Lilly | N/A | N/A |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Sivakumaran S, Cullen N, Lau C, Priest E, White H, Irizarry M, Klein G, Romero K, Leuzy A, Karten Y. . CRITICAL PATH FOR ALZHEIMER’S DISEASE (CPAD) CONSORTIUM: DATA-DRIVEN SOLUTIONS FOR CLINICAL TRIAL DESIGN AND INFORMED DECISION MAKING 16th Clinical Trials on Alzheimer’s Disease (CTAD). Boston, MA (USA) October 24-27, 2023. PO33. S85. Posters. J Prev Alzheimers Dis 10 (Suppl 1). Doi: 10.14283/jpad.2022.130 | Lilly | N/A | N/A |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Lupton Brantner, C., Quynh Nguyen, T., Tang, T., Zhao, C., Hong, H. and Stuart, E.A., 2023. Comparing Machine Learning Methods for Estimating Heterogeneous Treatment Effects by Combining Data from Multiple Randomized Controlled Trials. arXiv e-prints, pp.arXiv-2303. Doi: 10.48550/arXiv.2303.16299 | Johnson & Johnson, Lundbeck, Takeda | 3 | N/A |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | A. Salter, S. Lancia, K. Kowalec, K. Fitzgerald, R. A. Marie. O107/355 Prevalence of Comorbidities in Phase III Clinical Trials for Disease-Modifying Therapies in Multiple Sclerosis. MSMilan2023 – Oral Presentations. Multiple Sclerosis Journal, vol. 29 no. 3_suppl. Pp 4-136. Page 82. Doi: 10.1177/13524585231196191 | Roche | 0 | N/A |
| 7654 | Shirley Yu | University of Sydney | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Shirley PY, van Middelkoop M, Ferreira ML, Deveza L, Bierma-Zeinstra SM, Venkatesha V, Hunter DJ. The OA Trial Bank: Update of individual patient data meta-analysis of intra-articular glucocorticoids in persons with knee and hip osteoarthritis. Osteoarthritis and Cartilage Open. 2023 Apr 11:100362. doi: 10.1016/j.ocarto.2023.100362 | Sanofi | N/A | 0 |
| 7654 | Shirley Yu | University of Sydney | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Yu, S., Van Middelkoop, M., Ferreira, M., Deveza, L., Bierma-Zeinstra, S.M.A., Venkatesha, V. and Hunter, D., 2023. POS1362 THE OA TRIAL BANK: UPDATE OF INDIVIDUAL PATIENT DATA META-ANALYSIS OF INTRA-ARTICULAR GLUCOCORTICOIDS IN PERSONS WITH KNEE AND HIP OSTEOARTHRITIS. Doi: 10.1136/annrheumdis-2023-eular.1812 | Sanofi | 0 | N/A |
| 7658 | Arman Sabbaghi | Purdue University | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Jiang S., Liu B., Nei L., Sabbaghi A., Abdul Wahab A.H., Qu Y., Lyu T., Zhuang R. Is good enough good enough: A comprehensive evaluation of ICH E9 (R1) Strategies. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. PS5C. 2023. | Sanofi | N/A | NA |
| 7660 | Shirley Yu | University of Sydney | Predictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysis | Yu SP, van Middelkoop M, Deveza LA, Ferreira ML, Biermaâ€Zeinstra S, Zhang W, Atchia I, Birrell F, Bhagavath V, Hunter DJ. Predictors of placebo response to local (intraâ€articular) therapy in osteoarthritis–an individual participant data metaâ€analysis. Arthritis Care & Research. 2023 Jul 31. doi: 10.1002/acr.25212 | Sanofi | 13 | 2 |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | Hopkins, A.M., Modi, N. and Sorich, M.J., 2023. Is there a harmonised standard to oncology trial data provision in data sharing initiatives?. Doi: 10.1200/JCO.2023.41.16_suppl.e13645 | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, Takeda | 0 | N/A |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | Hopkins AM, Modi ND, Abuhelwa AY, et al. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages. JAMA Oncol. 2023. doi: 10.1001/jamaoncol.2023.3996 | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche, Sanofi, Takeda | 66 | 2 |
| 7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis | Kiely, M., Tadount, F., Lo, E., Sadarangani, M., Wei, S.Q., Rafferty, E., Quach, C. and MacDonald, S.E., 2023. Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. J Epidemiol Community Health. Doi: 10.1136/jech-2023-220781 | Sanofi | 295 | 2 |
| 7772 | Neeraj Narula | Hamilton Health Sciences | Combined Histologic and Endoscopic Endpoints in Ulcerative Colitis | Emily C L Wong, BHSc, Parambir S Dulai, MD, Badar Hasan, MD, John K Marshall, MD, MSc, FRCPC, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH, FRCPC. Combined Histologic and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared to Endoscopic Improvement Alone in Ulcerative Colitis: A Post-hoc Analysis of the VARSITY study. Journal of Crohn's and Colitis, 2023;, jjad033. doi: 10.1093/ecco-jcc/jjad033 | Takeda | 0 | 2 |
| 7797 | Jörg Ellinger | University Hospital Bonn | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Jonas Saal, Tobias Bald, Markus Eckstein, Manuel Ritter, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper. Early CRP kinetics predicts immunotherapy response in NSCLC in the phase III OAK trial. JNCI Cancer Spectrum, 2023;, pkad027. doi : 10.1093/jncics/pkad027 | Roche | 8 | 6 |
| 7809 | David James Pinato | Imperial College, London | The predictive role of concomitant antibiotics in patients treated with immunotherapy or oral treatment for unresectable hepatocellular carcinoma (HCC) | Claudia A.M. Fulgenzi, Cian Murphy, Antonio D’Alessio, Bernhard Scheiner, Matthias Pinter, Alessio Cortellini, David J. James Pinato. Effect of early antibiotic exposure on survival of patients receiving atezolizumab plus bevacizumab but not sorafenib for unresectable HCC: A sub-analysis of the phase III IMbrave150 study. J Clin Oncol 41, 2023 (suppl 4; abstr 597). doi: 10.1200/JCO.2023.41.3_suppl.597. | Roche | 0 | N/A |
| 7817 | Neeraj Narula | Hamilton Health Sciences | Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis | Wong, E.C., Gleave, A.L., Marshall, J.K. and Narula, N., Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis. European Journal of Gastroenterology & Hepatology, pp.10-1097. Doi: 10.1097/MEG.0000000000002623 | GlaxoSmithKline | 0 | 1 |
| 7822 | Linbin Lu | The 900th Hospital of PLA | Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment | Lu, L., Zheng, P., Pan, Y., Huang, S., Shao, E., Huang, Y., Wang, X., Chen, Y., Cuo, G., Yang, H. and Guo, W., 2023. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study. British Journal of Cancer, 129(4), pp.620-625. Doi: 10.1038/s41416-023-02334-7 | Roche | 0 | 3 |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | Mallity, C., Collins, E., Siegal, D., Wang, T., Carrier, M. and Xu, Y., 2023. IMPACT OF ANTICOAGULANTS FOR ARTERIAL THROMBOEMBOLISM PREVENTION AMONG AMBULATORY CANCER PATIENTS BY PRIMARY TUMOUR SITE: SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Diabetes, 47(7), pp.S209-S210. Doi: 10.1016/j.jcjd.2023.10.390 | GlaxoSmithKline, Sanofi | 0 | N/A |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | Mallity, C., Collins, E., Siegal, D., Wang, T., Carrier, M. IMPACT OF ANTICOAGULANTS FOR ARTERIAL THROMBOEMBOLISM PREVENTION AMONG AMBULATORY CANCER PATIENTS BY PRIMARY TUMOUR SITE: SYSTEMATIC REVIEW AND META-ANALYSIS. Canadian Journal of Cardiology, Volume 39, Issue 10, S252 - S253. doi: 10.1016/j.cjca.2023.06.405 | GlaxoSmithKline, Sanofi | 0 | N/A |
| 7856 | Evandro de Azambuja | Institut Jules Bordet | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Debien, V., Agostinetto, E., Bruzzone, M., Ceppi, M., Molinelli, C., Branco, D.M., Jacobs, F., Marta, G.N., Lambertini, M. and de Azambuja, E., 2023. 228P The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: An exploratory analysis of the CLEOPATRA trial. ESMO Open, 8(1). doi.org/10.1016/j.esmoop.2023.101417 | Roche | 0 | N/A |
| 7858 | Jie Zha | Xiamen University | Retrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patients | Zha, J., Chen, Q., Zhang, W., Jing, H., Ye, J., Yu, H., Yi, S., Li, C., Zheng, Z., Xu, W. and Li, Z., 2023. Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma. Blood, 142(Supplement 1), pp.3048-3048. Doi: 10.1182/blood-2023-182812 | Roche | https://www.altmetric.com/details/164189853?src=bookmarklet1 | N/A |
| 7868 | Anne-Marie Dingemans | Erasmus MC University Medical Center | Predictive clinical characteristics for weight gain in patients treated with alectinib | Sikkema, B.J., Baart, S.J., Paats, M.S., Smit, E.F., Schols, A.M., Mathijssen, R.H., van Rossum, E.F. and Dingemans, A.C., 2023. 1367P Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453. Annals of Oncology, 34, p.S785. Doi : 10.1016/j.annonc.2023.09.2400 | Roche | 0 | N/A |
| 7875 | Marco Valgimigli | Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI) | P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) | Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AÃ…, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051 | Sanofi | 326 | 27 |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | Doyle, F. Byrne, D., Boland F. 2023. Do psychometrics matter? The effects of advanced psychometrics on antidepressant randomised trial outcomes. International Society for Affective Disorders. Abstract O-02. pg.47 | GlaxoSmithKline, Lilly, Pfizer, Takeda | N/A | N/A |
| 8294 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib | Dulai, P.S., Wong, E.C., Johnson, B., Cox, K., Theriault, N., Stefan, M., Eldasher, L.M. and Narula, N., 2023. Su1712 AN ULCERATIVE COLITIS DECISION SUPPORT TOOL PREDICTS DRUG SPECIFIC ENDOSCOPIC REMISSION AND IMPROVES PROVIDER MASTERY IN TREATMENT SELECTION. _x000D_ _x000D_ Gastroenterology, 164(6), pp.S-647._x000D_ | Pfizer | N/A | N/A |
| 8325 | Xiaodan Tang | Northwestern University | Does scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory | Tang, X., Schalet, B.D., Peipert, J.D. and Cella, D., 2023. Does scoring method impact estimation of significant individual changes assessed by patient-reported outcome measures? Comparing Classical Test Theory versus Item Response Theory. Value in Health. doi:10.1016/j.jval.2023.06.002 | Abbvie | 0 | 0 |
| 8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Song, Y.S., Yang, H., Kang, B., Cheon, J., Kim, I., Kim, H., Lee, W.S., Sang, Y.B., Jung, S., Lim, H.Y. and Gaillard, V.E., 2023. Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Doi: 10.1159/000531182 | Roche | 0 | N/A |
| 8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Song, Y.S., Yang, H., Kang, B., Cheon, J., Kim, I., Kim, H., Lee, W.S., Sang, Y.B., Jung, S., Lim, H.Y. and Gaillard, V.E., 2023. 993P - Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Annals of Oncology (2023) 34 (suppl_2): S594-S618. | Roche | N/A | N/A |
| 8542 | João Sérgio Neves | Faculty of Medicine of University of Porto | Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use | Neves, J.S., Borges-Canha, M., Vasques-Nóvoa, F., Green, J.B., Leiter, L.A., Granger, C.B., Carvalho, D., Leite-Moreira, A., Hernandez, A.F., Del Prato, S. and McMurray, J.J., 2023. GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with Type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp.517-525. Doi: 10.1016/j.jacc.2023.05.048 | GlaxoSmithKline | 19 | 5 |
| 8555 | Gijsbert Stoet | University of Essex | Effects of exercise on blood glucose levels, food intake and insulin use in adult T1D patients | Stoet, G. and Holt, R.I., 2023. Characteristics of People with Optimally-Managed Type 1 Diabetes. Diabetes Epidemiology and Management, p.100153. doi: 10.1016/j.deman.2023.100153 | Jaeb Center for Health Research Foundation, Inc. | 0 | N/A |
| 8559 | Dag Aarsland | King’s College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Xue L, Bocharova M, Young AH, Aarsland D. G18 CLINICAL FACTORS AFFECTING COGNITIVE IMPROVEMENT OF VORTIOXETINE AND DULOXETINE IN ELDERLY PATIENTS WITH MAJOR DEPRESSIVE DISORDER. BAP2023_abstract book, pg A113. | Lundbeck | N/A | N/A |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Ritter, M., Brossart, P., Grünwald, V., Hölzel, M., Ellinger, J. and Klümper, N., 2023. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA oncology. doi : 10.1016/j.euo.2023.11.005 | Roche | 5 | 2 |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal, J., Bald, T., Eckstein, M., Ralser, D.J., Brossart, P., Ellinger, J., Hölzel, M. and Klümper, N., 2023. 1480P Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors. Annals of Oncology, 34, p.S837. Doi: 10.1016/j.annonc.2023.09.2511 | Roche | https://www.altmetric.com/details/166789543?src=bookmarklet1 | 0 |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Saal J., Bald T., Eckstein M., Ralser D., Brossart P., Grünwald V., Hölzel M., Ellinger J. Klümper N. Multi-modal staging in immunotherapy - integrating the on-treatment modi ed Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma. Oncology Research and Treatment. 2023. (suppl 5):1–354 Pg. 77 Abstract V511. Doi: 10.1159/000533576 | Roche | https://www.altmetric.com/details/166943750?src=bookmarklet1 | https://pubmed.ncbi.nlm.nih.gov/37788643/0 |
| 8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Alfehaid L, Alkhezi O, Buckley L, Libby P, Desai A, Tawifk Y, Shah A. COLCHICINE, DRUG-DRUG INTERACTIONS AND GASTROINTESTINAL ADVERSE EFFECTS. American College of Clinical Pharmacy. Session IV. 2023. | Montreal Heart Institute | N/A | N/A |
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetrics Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3369 | Michael Ward | National Institutes of Health (NIH) | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis | Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022;5(3):e222312. doi: 10.1001/jamanetworkopen.2022.2312 | AbbVie, Pfizer | 33 | 10 |
| 4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center | Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trials | L Vogel, I Dykun, P Raggi, A Schmermund, T Rassaf, A Mahabadi. High- vs. low-intensity statin therapy and changes in coronary artery calcification density after one year. European Heart Journal, Volume 43, Issue Supplement_2, October 2022, ehac544.209. doi: 10.1093/eurheartj/ehac544.209 | Pfizer | 1 | N/A |
| 4116 | Sharon Strauss | St. Michael’s Hospital | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis | Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012. doi: 10.1136/bmjopen-2021-053012 | AbbVie | 56 | 45 |
| 4120 | Merryn Voysey | University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Shuo Feng, Julian Higgins, Maria Knoll, Julie Mclellan, Kim Muholland, Nicola Pidduck, Andrew Pollard, Beth Temple, Merryn Voysey. COMPARISON OF IMMUNOGENICITY AND SEROEFFICACY BETWEEN TEN- AND THIRTEEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINES – A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. ESPID-2022-Abstracts-Book. Page 294 PD103 / #743. | Pfizer | N/A | N/A |
| 4316 | Martin Okun | Fort Healthcare | Geospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis. | Okun TSD, Okun MM. No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated. Journal of Psoriasis and Psoriatic Arthritis. January 2022. doi: 10.1177/24755303221079810 | AbbVie | 2 | N/A |
| 4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Gewandter JS, Sohn MB, De Guzman R, Frazer ME, Chiodo V, Sharma S, Geha P, Markman JD. Predicting treatment response with sensory phenotyping in post-traumatic neuropathic pain. Pain Med. 2022 Mar 21:pnac045. PMID: 35312012. doi: 10.1093/pm/pnac045 | Pfizer | 14 | 2 |
| 4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Olaposi Peters, John Markman, Michael Sohn, Rachel De Guzman, Maria Frazer, Valerie Chiodo, Sonia Sharma, Paul Geha, Jennifer Gewandter. Predicting treatment response with sensory phenotyping in posttraumatic neuropathic pain. CPS 2022 Book of Abstracts Final, page 277. | Pfizer | N/A | N/A |
| 4329 | Shomron Ben-Horin | Sun Yatsen 1st affiliated Hospital | Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease | Shomron Ben-Horin, Lena Novack, Ren Mao, Jing Guo, Yue Zhao, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi, Yehuda Chowers, Laurent Peyrin-Biroulet, Jean Frederic Colombel, Gilaad G. Kaplan, Min-hu Chen. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology, 2021, ISSN 0016-5085. doi: 10.1053/j.gastro.2021.10.037 | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB | 35 | 27 |
| 4921 | Tim Brümmendorf | University Hospital Aachen | Entropy-based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML | Esfahani, Ali, Susanne Isfort, Tim Brümmendorf, and Andreas Schuppert. Entropy-based Biomarkers for Individualized Response on Bosutinib Treatment in Chronic Phase CML. OSF Preprints. March 1, 2022. doi:10.31219/osf.io/bu2qy | Pfizer | 1 | N/A |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | Takase-Minegishi K, Böhringer S, Nam J, Kaneko Y, Behrens F, Saevarsdottir S, Detert J, Leirisalo-Repo M, van der Heijde D, Landewé R, Ramiro S, van der Woude D. The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-autoantibodies-rf-and-acpa-on-the-efficacy-of-biological-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-meta-analysis-of-randomized-controlled-trials/. | AbbVie, Pfizer | N/A | N/A |
| 5086 | Junko Takeshita | University of Pennsylvania | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | Sevagamoorthy A, Sockler P, Akoh C, Takeshita J. Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. J Dermatolog Treat. 2022 Aug 31:1-12 doi : 10.1080/09546634.2022.2114783 | AbbVie, Lilly, Regeneron | 21 | 5 |
| 5163 | Susan Bates | Columbia University Medical Center | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Celine Yeh, Mengxi Zhou, Keith Sigel, Gayle Jameson, Ruth White, Rachael Safyan, Yvonne Saenger, Elizabeth Hecht, John Chabot, Stephen Schreibman, Béata Juzyna, Marc Ychou, Thierry Conroy, Tito Fojo, Gulam A Manji, Daniel Von Hoff, Susan E Bates. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data. The Oncologist, 2022. doi : 10.1093/oncolo/oyac217 | Bristol Meyers Squibb | 1 | 1 |
| 5165 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat | Ghang B, Lee JS, Choi J, et al. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open 2022;8:e001944 doi: 10.1136/rmdopen-2021-001944 | Takeda | 5 | 6 |
| 5207 | Fasihul Khan | University of Nottingham | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | Khan FA, Stewart I, Moss S, Fabbri L, Robinson KA, Johnson SR, Jenkins RG. Three-Month FVC Change: A Trial Endpoint for IPF Based on Individual Participant Data Meta-Analysis. Am J Respir Crit Care Med. 2022 Jan 12. doi: 10.1164/rccm.202109-2091OC | BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche | 10 | 6 |
| 5291 | Sarah Nevitt | University of Liverpool | Antiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis | Nevitt SJ, Sudell M, Cividini S, Marson AG, Tudur Smith C. Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD011412. doi: 10.1002/14651858.CD011412.pub4 | UCB | 42 | 30 |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach | Duong, S.Q., Crowson, C.S., Athreya, A., Atkinson, E.J., Davis, J.M., Warrington, K.J., Matteson, E.L., Weinshilboum, R., Wang, L. and Myasoedova, E. Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Res Ther 24, 162 (2022). doi: 10.1186/s13075-022-02851-5 | Roche, UCB | 1 | 11 |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach | Duong S, Crowson CS, Athreya A, et al. POS0514 PREDICTION OF RESPONSE TO METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A MACHINE LEARNING APPROACH USING CLINICAL TRIAL DATA. Annals of the Rheumatic Diseases 2022;81:513-514. doi:10.1136/annrheumdis-2022-eular.891 | Roche, UCB | 1 | 11 |
| 5456 | Terina Martinez | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | R. Belfiore-Oshan, V. Aggarwal, S. Sivakumaran, D. Corey, C. Ollivier, K. Romero, K. Vandenborne, S. Kim, J. Morales, K. Lingineni, T. Martinez. VP.85. C-Path's Duchenne Regulatory Science Consortium: Accelerating drug development for Duchenne muscular dystrophy. Neuromuscular Disorders, Volume 32, Supplement 1. 2022. Page S128. doi: 10.1016/j.nmd.2022.07.359 | CureDuchenne | N/A | N/A |
| 5456 | Terina Martinez | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Varun Aggarwal, Rhoda Muse, Sarah Kim, Jackson Burton, Diane Corey, Lauren Quinlan, Klaus Romero, Ramona Belfiore-Oshan, Terina Martinez. Multivariate Joint Models to Predict Clinically Meaningful Decline in Duchenne Muscular Dystrophy as measured by NSAA Using Timed Function Test Trajectories. ACoP13 (2022) STPM-328. | CureDuchenne | N/A | N/A |
| 5812 | Yougen Wu | The Fifth People's Hospital of Shanghai, Fudan University | Development and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors | Wu Y, Zhu W, Wang J, Liu L, Zhang W, Wang Y, Shi J, Xia J, Gu Y, Qian Q, Hong Y. Using machine learning for mortality prediction and risk stratification in atezolizumab-treated cancer patients: Integrative analysis of eight clinical trials. Cancer Med. 2022 Jul 24. doi: 10.1002/cam4.5060 | Roche | 11 | 6 |
| 5853 | Florian Naudet | CHU Rennes | Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment Reports | Siebert, M., Gaba, J., Renault, A. et al. Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports. BMC Med 20, 177 (2022). doi:10.1186/s12916-022-02377-2 | AbbVie | 29 | 4 |
| 5869 | Alexandra Freeman | University of Cambridge | Meta-analysis of the adverse effects of trastuzumab in women with breast cancer | Jackson, C., Finikarides, L. and Freeman, A., 2022. The adverse effects of trastuzumab-containing regimes as a therapy in breast cancer: a piggy-back systematic review and meta-analysis. doi: 10.1371/journal.pone.0275321 | Roche | 4 | 7 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Eugene Tan, Ahmad Y. Abuhelwa, Sarah Badaoui, Natansh D. Modi, Michael D. Wiese, Ross A. McKinnon, Michael J. Sorich and Ashley M. Hopkins. Association Between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab. 1 Jan, 2021 : 1 doi: 10.3233/BLC-211613 | Roche | 3 | N/A |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Badaoui S, Shahnam A, McKinnon RA, Abuhelwa AY, Sorich MJ, Hopkins AM. The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy. Transl Lung Cancer Res 2022;11(3):432-439. doi: 10.21037/tlcr-21-9385 | Roche | 2 | 12 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Hopkins, A. M., Badaoui, S., Kichenadasse, G., Karapetis, C. S., McKinnon, R. A., Rowland, A., & Sorich, M. J. (2022). Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials. Journal of Thoracic Oncology. doi: https://doi.org/10.1016/j.jtho.2022.02.003 | Roche | 13 | 17 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Abuhelwa AY, Bellmunt J, Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM. C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab. Front Oncol. 2022 Aug 1;12:918993. doi: 10.3389/fonc.2022.918993 | Roche | 5 | 4 |
| 5902 | Thrasyvoulos Tzellos | Norland University Hospital | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | Thrasivoulos Tzellos Et al. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022 Oct 2. doi: 10.1111/jdv.18632. Online ahead of print. | AbbVie | 6 | 12 |
| 5902 | Thrasyvoulos Tzellos | Norland University Hospital | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | K. R. van Straalen, T. Tzellos, A. Alavi, F. Benhadou, C. Cuenca-Barrales, M. Daxhelet, M. Daoud, O. Efthymiou, E. J. Giamarellos-Bourboulis, P. Guillem, W. Gulliver, G. B. Jemec, A. Katoulis, A. Koenig, E. Lazaridou, M. Lowes, A. V. Marzano, L. Matusiak, A. Molina-Leyva, C. Moltrasio, A. Pinter, C. Potenza, E. P. Prens, J. Romaní, D. M. Saunte, C. J. Sayed, N. Skroza, D. Stergianou, J. C. Szepietowski, A. Trigoni, E. Vilarrasa, H. H. van der Zee, A. Kyrgidis, C. C. Zouboulis. (2022), 11th EHSF Conference 2022 Abstracts. Exp Dermatol, 31: 40-125. S-01-12 – Development and validation of an IHS4 dichotomous outcome to assess treatment effect. (p.47). Doi: 10.11111/exd.14557 | AbbVie | 3 | N/A |
| 5933 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Manning-Bennett, A. T., Hopkins, A. M., Sorich, M. J., Proudman, S. M., Foster, D. J. R., Abuhelwa, A. Y., & Wiese, M. D. (2022). The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis – a pooled analysis of five randomised controlled trials. Therapeutic Advances in Musculoskeletal Disease. doi:10.1177/1759720X221111613 | Roche | 1 | 10 |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Daraghmeh DN, Hopkins AM, King C, Abuhelwa AY, Wechalekar MD, Proudman SM, Sorich MJ, Wiese MD. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2022 Jun 22:keac357. doi : 10.1093/rheumatology/keac357 | Roche | 245 | 2 |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Manning-Bennett A, Hopkins A, Sorich M, Proudman S, Foster D, Abuhelwa A, Wiese M. The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis [abstract]. Arthritis Rheumatol. 20 22; 74 (suppl 9). https://acrabstracts.org/abstract/the-association-of-cardiovascular-comorbidities-with-remission-in-rheumatoid-arthritis-patients-undergoing-treatment-with-baricitinib-and-conventional-synthetic-dmards-a-post-hoc-analysis/ | Lilly | N/A | N/A |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou J, Yang J, Wang H, et al. Machine learning based on blood biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy. Annals of Oncology (2022) 33 (suppl_2): S27-S70. doi: 10.1016/j.annonc.2022.02.069 | Roche | 0 | N/A |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Ma, SC., Bai, X., Guo, XJ., Liu, L., Xiao, LS., Lin, Y., Tan, JL., Cai, XT., Wen, YX., Ma, H., Fu, QJ., Leng, MX., Zhang, YP., Long, LL., Guo, ZQ., Wu, DH., Zhou, JG., Dong, ZY. Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC Med 20, 120 (2022). doi: 10.1186/s12916-022-02315-2 | Roche | 5 | 8 |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Development and validation of longitudinal c-reactive protein as dynamic response predictor for PD-L1 blockade in advanced NSCLC: Findings from four atezolizumab clinical trials. Jian-Guo Zhou, Xiaofei Chen, Ada Hang-Heng Wong, Haitao Wang, Fangya Tan, Si-Si He, Gang Shen, YunJia Wang, Ruihong Wang, Shamus R. Carr, Benjamin Frey, Rainer Fietkau, Markus Hecht, Hu Ma, David S. Schrump, and Udo S Gaipl. Journal of Clinical Oncology 2022 40:16_suppl, e21113-e21113. doi: 10.1200/JCO.2022.40.16_suppl.e21113. | Roche | 1 | N/A |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, J.G., Wong, A.H.H., Wang, H., Tan, F., Chen, X., Jin, S.H., He, S., Shen, G., Wang, Y.J., Frey, B. and Fietkau, R. Elucidation of the application of blood test biomarkers to predict immune-related adverse events (irAEs) in atezolizumab-treated NSCLC patients by using machine learning methods. Frontiers in Immunology, p.3081. doi: 10.3389/fimmu.2022.862752 | Roche | 4 | 9 |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou J, Wong A, Wang H, Jin S, Tan F, Chen Y, He S, Shen G, Frey B, Fietkau R, Hecht M, Carr S, Wang R, Shen B, Schrump D, Ma H and Gaipl US(2022) Definition of a new blood cell count (BCT) score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of 4 multicenter clinical trials. Front. Immunol. 13:961926. doi:10.3389/fimmu.2022.961926 | Roche | 2 | 1 |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou, Jian-Guo and Yang, Jie and Wang, Haitao and Wong, Ada Hang-Heng and Tan, Fangya and Chen, Xiaofei and he, sisi and Shen, Gang and Wang, Yun-Jia and Frey, Benjamin and Fietkau, Rainer and Hecht, Markus and Zhong, Wen-Zhao and Ma, Hu and Gaipl, Udo. Machine Learning Based on Blood Test Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy. DOI : 10.2139/ssrn.4214527 | Roche | 1 | N/A |
| 5945 | Neeraj Narula | McMaster University | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Wong ECL, Dulai PS, Narula N. Correspondence on "PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system" by Gui et al. Gut. 2022 Jun 7. gutjnl-2022-327661. doi: 10.1136/gutjnl-2022-327661 | Takeda | 2 | 0 |
| 5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | de Winter, M.A., Uijl, A., Büller, H.R., Carrier, M., Cohen, A.T., Hansen, J.B., Kaasjager, K.H., Kakkar, L.A.K., Middeldorp, S., Raskob, G.E. and Sørensen, H.T., 2022. Redefining clinical venous thromboembolism phenotypes: a novel approach using latent class analysis. Journal of Thrombosis and Haemostasis. doi: 10.1016/j.jtha.2022.11.013 | Daiichi Sankyo | 0 | N/A |
| 5959 | John Dennis | University of Exeter Medical School | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | Dennis, J.M., Young, K.G., McGovern, A.P., Mateen, B.A., Vollmer, S.J., Simpson, M.D., Henley, W.E., Holman, R.R., Sattar, N., Pearson, E.R. and Hattersley, A.T., 2022. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. The Lancet Digital Health, 4(12), pp.e873-e883. doi: 10.1016/S2589-7500(22)00174-1 | Boehringer Ingelheim | 34 | 9 |
| 5984 | David Baker | Queen Mary University of London | Exploring possibilities to improve the risk benefit balance through analysis of the ocrelizumab phase II extension study | Baker, D., MacDougall, A., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2022). CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 57, 103448. doi: 10.1016/j.msard.2021.103448 | Roche | 26 | 14 |
| 6004 | Lily Lim | University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Lim LSH, Shobhan S, Lokku A, Ringold S, Pullenayegum E. Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials. Pediatr Rheumatol Online J. 2022 Jul 30;20(1):57. doi: 10.1186/s12969-022-00719-1 | Roche | 1 | 0 |
| 6004 | Lily Lim | University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Lim, L. S. H., Lokku, A., Pullenayegum, E., & Ringold, S. Probability of Response in the First 16 Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials. Arthritis Care & Research. doi: 10.1002/acr.25003 | Roche | 11 | N/A |
| 6006 | Nicholas White | Mahidol University | A Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 | Chotsiri, P., Tarning, J., Hoglund, R.M., Watson, J. and White, N.J. (2022), Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. Clin Pharmacol Ther. doi:10.1002/cpt.2665 | Pfizer | 9 | 1 |
| 6007 | Judith Goldstein | Johns Hopkins School of Medicine | National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) | Judith E. Goldstein, Chris Bradley, Alden L. Gross, Marylou Jackson, Neil Bressler, Robert W. Massof; The NEI VFQ-25C: Calibrating Items in the National Eye Institute Visual Function Questionnaire-25 to Enable Comparison of Outcome Measures. Trans. Vis. Sci. Tech. 2022;11(5):10. doi: 10.1167/tvst.11.5.10. | Roche | 2 | 11 |
| 6041 | Neeraj Narula | Hamilton Health Sciences | Histologic Predictors of Endoscopic Healing in Crohn's Disease | Emily C L Wong, BHSc, Arif Yusuf, MD, Jagoda Pokryszka, MD, Parambir S Dulai, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease. Inflammatory Bowel Diseases. 2022, izac157. doi: 10.1093/ibd/izac157, doi: 10.1093/ibd/izac208 | AbbVie | 0 | 1 |
| 6062 | Alexander Meisel | University Hospital of Zurich | Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | A. Meisel, M.T. Mark, A. Haider, L. Holer, S. Hayoz, C. Gebhard, S. Bengs, V. Treyer, S.I. Rothschild, M.J. Hochmair, D.R. Gandara, F. Cappuzzo, M. Reck, F. Stenner-Liewen, R.A.F. von Moos. 1051P - Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and hemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC). Annals of Oncology (2022) 33 (suppl_7): S 448-S554. | Roche | N/A | N/A |
| 6494 | Maria Alice Franzoi | Jules Bordet Institute | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. 2022 Jan 25. doi: 10.1007/s10549-022-06525-3. | Lilly | 1 | 4 |
| 6494 | Maria Alice Franzoi | Jules Bordet Institute | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Maria Alice Franzoi, Matteo Lambertini, Marcello Ceppi, Marco Bruzonne, Evandro de Azambuja. Abstract P5-13-07: Implications of body mass index (BMI) on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting. Cancer Res, 15 February 2022; 82 (4_Supplement): P5–13–07. doi: 10.1158/1538-7445.SABCS21-P5-13-07 | Lilly | 1 | N/A |
| 6496 | Neeraj Narula | Hamilton Health Sciences | Endoscopic Disease Severity and Patient Reported Outcomes in Crohns Disease | Cara Pray, MD, Emily C L Wong, BHSc, Achuthan Aruljothy, MDCM, Parambir S Dulai, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH. Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis. Inflammatory Bowel Diseases, 2022. izac210 doi : 10.1093/ibd/izac210 | AbbVie, Johnson & Johnson | 0 | 0 |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | N.D. Modi, N.O. Danell, R.N.A. Perry, A.Y. Abuhelwa, A. Rathod, S. Badaoui, R.A. McKinnon, M. Haseloff, A. Shahnam, S.M. Swain, M. Welslau, M.J. Sorich, A.M. Hopkins, "Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer", ESMO Open, Volume 7, Issue 3, 2022, 100475. doi:10.1016/j.esmoop.2022.100475 | Roche | 76 | 5 |
| 6532 | Odelia Cooper | Cedars-Sinai Medical Center | A study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumors | Odelia Cooper, Sungjin Kim. ODP643 Metabolic Effects of Growth Hormone Replacement in Craniopharyngioma and Pituitary Adenoma Patients: Analysis of the Hypopituitary Control and Complications Study (HypoCCS) Database. Journal of the Endocrine Society, Volume 6, Issue Supplement_1, November-December 2022, Page A521. doi: 10.1210/jendso/bvac150.1085 | Lilly | 1 | N/A |
| 6543 | Andreas Meid | Heidelberg University Hospital | Reproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) – can ML methods support the validity of conventional TGI metrics? | Meid, A., Gerharz, A., Groll, A. Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility. CPT: Pharmacometrics & Systems Pharmacology. 2022 Feb 01. doi: 10.1002/psp4.12761 | Roche | 2 | 3 |
| 6601 | Dan Turner | Shaare Zedek Medical Center | Adaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data | Dotan Yogev, MD, Bram Verstockt, MD, PhD, Axel Dignass, MD, PhD, Gili Focht, MSc, MBA, Ohad Atia, MD, Iris Dotan, MD, PhD, Severine Vermeire, MD, PhD, Dan Turner, MD, PhD. The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn’s Disease. Inflammatory Bowel Diseases, 2022;. izac235. doi : 10.1093/ibd/izac235 | AbbVie | 1 | 0 |
| 6632 | Luca Valerio | University Medical Center of the Johannes Gutenberg-University Mainz | Healthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in venous thromboembolism (VTE) study | Farmakis IT, Barco S, Mavromanoli AC, Agnelli G, Cohen AT, Giannakoulas G, Mahan CE, Konstantinides SV, Valerio L. Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry. J Am Heart Assoc. 2022 Oct 18;11(20):e027514. doi : 10.1161/JAHA.122.027514 | Daiichi Sankyo | 5 | 6 |
| 6633 | Luca Valerio | University Medical Center Mainz | Performance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study | Farmakis IT, Barco S, Mavromanoli AC, Konstantinides SV, Valerio L. Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study. JACC CardioOncol. 2022 Nov 15;4(4):507-518. doi: 10.1016/j.jaccao.2022.07.008 | Daiichi Sankyo | 10 | 7 |
| 6710 | Gus Slotman | Inspira Health Network | Identifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality | Kelter, David MD; Slotman, Gus J MD, FACS. Smart Identifies Dichotomous Drotrecogin Alfa Activated Treatment Effects on Mortality in Prowess Shock. Journal of the American College of Surgeons: November 2022 - Volume 235 - Issue 5 - p S296. doi: 10.1097/01.XCS.0000895332.83940.b8 | Lilly | 1 | N/A |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Huang Y-C, Cheng Y-C, Jhou M-J, Chen M, Lu C-J. Important Risk Factors in Patients with Nonvalvular Atrial Fibrillation Taking Dabigatran Using Integrated Machine Learning Scheme—A Post Hoc Analysis. Journal of Personalized Medicine. 2022; 12(5):756. doi:10.3390/jpm12050756 | Boehringer Ingelheim | 1 | 9 |
| 6734 | Andreas Suhrbier | QIMR Berghofer Medical Research Institute | The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans | Bishop CR, Dumenil T, Rawle DJ, Le TT, Yan K, et al. Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. (2022). PLOS Pathogens 18(9): e1010867. Doi: 10.1371/journal.ppat.1010867 | Hannover Medical School | 4 | 16 |
| 6765 | Dan Hanley | Johns Hopkins University | Pandemic response COVID-19 Research Collaboration Platform | Di Stefano L, Ogburn EL, Ram M, Scharfstein DO, Li T, Khanal P, Baksh SN, McBee N, Gruber J, Gildea MR, Clark MR, Goldenberg NA, Bennani Y, Brown SM, Buckel WR, Clement ME, Mulligan MJ, O'Halloran JA, Rauseo AM, Self WH, Semler MW, Seto T, Stout JE, Ulrich RJ, Victory J, Bierer BE, Hanley DF, Freilich D. Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses. Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. PLoS One. 2022 Sep 29;17(9):e0273526. Doi: https://doi.org/10.1371/journal.pone.0273526 | NYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans | 29 | 6 |
| 6866 | Andy Lim | Monash University | Meta-analysis of early stroke recurrence rate in minor stroke | A. Lim, H. Ma, C. Johnson, S. Singhal, S. Muthusamy, Y. Wang, Y. Pan, S. Coutts, A. Ois, M.K Kapral, M. Knoflach, L.J Woodhouse, P.M Bath, T Phan. Ninety-day stroke recurrence rate in minor stroke: a meta-analysis of randomized trials and observational studies. European Stroke Journal. 2022;7(1_suppl):3-545. European Stroke Organisation Conference (ESOC) 2022 Abstract Book, O084 / 129 page 48. doi: 10.1177/23969873221087559. | AstraZeneca | 10 | N/A |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Ding, W.Y., Calvert, P., Gupta, D. et al. Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry. Clin Res Cardiol (2022). doi:10.1007/s00392-022-02022-1 | Boehringer Ingelheim | 4 | 7 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022 Aug 29. doi: 10.1055/s-0042-1756355 | Boehringer Ingelheim | 26 | 31 |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Ding WY, Lane DA, Gupta D, Huisman MV, Lip GYH, GLORIA‐AF Investigators. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry. J Am Heart Assoc. 2022 Aug 2;11(15):e026410. doi : 10.1161/JAHA.122.026410. | Boehringer Ingelheim | 14 | 11 |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | Wong, EC, Dulai, PS, Marshall, JK, Jairath, V, Reinisch, W, Narula, N. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease. Aliment Pharmacol Ther. 2022; 00: 1– 9. doi: 10.1111/apt.16805 | AbbVie, Johnson & Johnson | 8 | 1 |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | N Narula, C Pray, E Wong, J F Colombel, J Marshall, M Daperno, W Reinisch, P Dulai. DOP16 Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD). Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i065–i066. doi: 10.1093/ecco-jcc/jjab232.055 | AbbVie, Johnson & Johnson | 1 | N/A |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohn’s Disease | Neeraj Narula, Cara Pray, Emily C L Wong, Jean-Frederic Colombel, John K Marshall, Marco Daperno, Walter Reinisch, Parambir S Dulai. Categorising Endoscopic Severity of Crohn’s Disease Using the Modified Multiplier SES-CD [MM-SES-CD]. Journal of Crohn's and Colitis, 2022;, jjac018,. doi: 10.1093/ecco-jcc/jjac018 | AbbVie, Johnson & Johnson | 6 | 4 |
| 7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer | Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial. Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, Claudia A.M. Fulgenzi, Alfredo Addeo, Giuseppe Luigi L. Banna, and David J. James Pinato. Journal of Clinical Oncology 2022 40:16_suppl, 9056-9056. doi:10.1200/JCO.2022.40.16_suppl.9056 | Roche | 1 | N/A |
| 7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer | Cortellini, A., Ricciuti, B., Borghaei, H., Naqash, A.R., D'Alessio, A., Fulgenzi, C.A.M., Addeo, A., Banna, G.L. and Pinato, D.J. (2022), Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. doi: 10.1002/cncr.34348 | Roche | 24 | 13 |
| 7158 | Neeraj Narula | Hamilton Health Sciences | Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis | Emily Chu Lee Wong, Badar Hasan, Parambir S. Dulai, John K. Marshall, Walter Reinisch & Neeraj Narula. (2022). End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. Scandinavian Journal of Gastroenterology. DOI: 10.1080/00365521.2022.2105169 | Takeda | 1 | 1 |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | Associations Between Steroid Treatment and Clinical Outcomes Among Non-ambulatory Patients with Duchenne Muscular Dystrophy (DMD) (P1-1.Virtual). Craig McDonald, Oscar Mayer, Kan Hor, Jessica Marden, Jonathan Freimark, Henry Lane, Adina Zhang, Molly Frean, Claudio Santos, Richard Able, James Signorovitch. Neurology May 2022, 98 (18 Supplement) 1348 https://www.neurology.org/doi/10.1212/WNL.98.18_supplement.1348 | CureDuchenne | N/A | N/A |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | Associations Between Deflazacort Versus Prednisone/Prednisolone and Markers of Disease Progression in Clinically Important Subgroups of Patients with Duchenne Muscular Dystrophy (P1-1.Virtual). Craig McDonald, Jessica Marden, Henry Lane, Adina Zhang, Ha Nguyen, Claudio Santos, Richard Able, James Signorovitch. Neurology May 2022, 98 (18 Supplement) 1437 https://doi.org/10.1212/WNL.98.18_supplement.1437 | CureDuchenne | N/A | N/A |
| 7159 | James Signorovitch | Analysis Group | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | McDonald CM, Mayer OH, Hor KN, Miller D, Goemans N, Henricson EK, Marden JR, Freimark J, Lane H, Zhang A, Frean M, Trifillis P, Koladicz K, Signorovitch J; PRO-DMD-01 consortium investigators. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2023;10(1):67-79. doi : 10.3233/JND-221575. | CureDuchenne | 1 | 2 |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal J, Bald T, Hölzel M, Ritter M, Brossart P, Ellinger J, Klümper N. In the phase 3 IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. Ann Oncol. 2022 Jun 15:S0923-7534(22)01730-6. doi: 10.1016/j.annonc.2022.06.003 | Roche | 10 | 5 |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Saal J, Bald T, Hölzel M, Ritter M, Brossart P, Ellinger J, Klümper N. P229 Der modifizierte Glasgow Prognostic Score (mGPS) sagt das Überleben in Patienten mit metastasiertem Nierenzellkarzinom in der Phase III IMmotion151 Studie besser voraus als der IMDC score. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022. Oncol Res Treat 27 September 2022; 45 (Suppl. 2): 5–346, Page 318. doi: 10.1159/000526456 | Roche | 0 | 0 |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Narula, Neeraj MD, MPH, FRCPC; Wong, Emily C.L. BHSc; Marshall, John K. MD, MSc, FRCPC; Jairath, Vipul MD, PhD; Dulai, Parambir S. MD; Reinisch, Walter MD, PhD. Long-term Outcomes of Early Versus Delayed Responders to Vedolizumab and Adalimumab: A Post-hoc Analysis of VARSITY. The American Journal of Gastroenterology: September 1, 2022 - Volume - Issue - 10.14309/ajg.0000000000001987 doi : 10.14309/ajg.0000000000001987 | Takeda | 13 | 4 |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Z. Alhashimalsayed, E. C.L. Wong, W. Reinisch, N. Narula. MP444 SEX-BASED DIFFERENCES IN RESPONSE TO VEDOLIZUMAB THERAPY FOR ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF VARSITY AND GEMINI-1 STUDY. United European Gastroenterology Journal 2022; 10 (Supplement 8), October 2022. Moderated Posters p276/277. doi : 10.1002/ueg2.12294 | Takeda | 2 | N/A |
| 7241 | Frederick Reimherr | Psychiatric and Behavioral Solutions, LLC | Retrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole | Reimherr, Frederick W.; Gift, Thomas E.; Steans, Tammy A.; Reimherr, Matthew L.; Rosenberg, Leon I.; Wilson, Melissa; Marchant, Barrie K. The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology: August 17, 2022 - Volume - Issue - 10.1097/JCP.0000000000001592. doi : 10.1097/JCP.0000000000001592. | Otsuka | 8 | 2 |
| 7245 | Manabu Takaki | Okayama University | Clinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan | Nozomu Hashimoto, Hiroshi Habu, Soshi Takao, Shinji Sakamoto, Yuko Okahisa, Keitaro Matsuo, Manabu Takaki, Yoshiki Kishi, Norihito Yamada. Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: an exploratory analysis. Drug and Alcohol Dependence, 2022, 109365, ISSN 0376-8716. doi: 10.1016/j.drugalcdep.2022.109365 | Otsuka | 8 | 2 |
| 7387 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease | Narula, Neeraj; Wong, Emily C.L.; Dulai, Parambir S.; Marshall, John K.; Jairath, Vipul; Reinisch, Walter. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease. The American Journal of Gastroenterology: April 15, 2022 - Volume - Issue - 10.14309/ajg.0000000000001795. doi: 10.14309/ajg.0000000000001795 | AbbVie, Johnson & Johnson, Takeda | 43 | 13 |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Ghang B, Kim J, Yoo. BPOS0284 CHANGES OF ESTIMATED GLOMERULAR FILTRATION RATE AFTER LONG-TERM FEBUXOSTAT OR ALLOPURINOL TREATMENT IN GOUT PATIENTS. Annals of the Rheumatic Diseases 2022;81:386 . https://ard.bmj.com/content/81/Suppl_1/386.1.full | Takeda | 1 | N/A |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Byeongzu Ghang, Jinseok Kim. Effects of long-term febuxostat or allopurinol on the progression of chronic kidney disease. Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022 p271 O-54. https://kcr2022.com/download/KCR2022_Abstract%20Book.pdf?ver=8 | Takeda | N/A | N/A |
| 7414 | Nobuyuki Horita | Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis. | Horita, N. Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses. Cancers 2023, 15, 185. doi: 10.3390/cancers15010185 | Roche | 0 | 0 |
| 7414 | Nobuyuki Horita | Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis. | Ayaka Maeda, Kaoru Takase-Minegishi, Yohei Kirino, Naoki Hamada, Yosuke Kunishita, Ryusuke Yoshimi, Akira Meguro, Ho Namkoong, Nobuyuki Horita, Hideaki Nakajima, Yokohama City University irAE Working Group. Immune checkpoint inhibitor–induced arthralgia is tightly associated with improved overall survival in cancer patients. Rheumatology, 2022;. keac519. doi : 10.1093/rheumatology/keac519 | Roche | 1 | 2 |
| 7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease | Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N. Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 Aug 24:S1542-3565(22)00811-4. doi : 10.1016/j.cgh.2022.08.015 | AbbVie, Johnson & Johnson, Pfizer, Takeda | 5 | 1 |
| 7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease | Emily C L Wong, BHSc, Parambir S Dulai, MD, John K Marshall, MD, MSc, FRCPC, Vipul Jairath, MD, PhD, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH, FRCPC. Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease. Inflammatory Bowel Diseases. 2022. izac231. doi : 10.1093/ibd/izac231 | AbbVie, Takeda, Pfizer | 1 | 1 |
| 7609 | Joao Pedro Ferreira | Porto University | The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline | Ferreira JP, Sharma A, Vasques-Nóvoa F, Angélico-Gonçalves A, Leite AR, Borges-Canha M, Carvalho D, Packer M, Zannad F, Leite-Moreira A, Neves JS. Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes. Eur J Heart Fail. 2022 Aug 23. doi: 10.1002/ejhf.2660 | GlaxoSmithKline | 3 | 5 |
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetric Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3288 | Marc-Antoine Sparfel | Tours Hospital | MIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trials | Law-Wan J, Sparfel M, Derolez S, et al. Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. RMD Open 2021;7:e001882. doi: 10.1136/rmdopen-2021-001882 | AbbVie, Pfizer, UCB | 4 | 7 |
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | Frew, J. W., Singh, N., Jiang, C. S., Vaughan, R., & Krueger, J. G. (2021). The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa. Frontiers in Medicine. doi: 10.3389/fmed.2021.603281 | AbbVie | 2 | 3 |
| 3762 | Lin Wang | Johns Hopkins School of Public Health, Johns Hopkins Hospital | The relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer | Lin Wang, MD, PhD, Channing Paller, MD, Hwanhee Hong, PhD, Lori Rosman, MLS, Anthony De Felice, MHS, Otis Brawley, MD, G Caleb Alexander, MD, MS, Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis, JNCI: Journal of the National Cancer Institute, 2021;, djab071, doi: 10.1093/jnci/djab071 | Pfizer, Project Data Sphere | 21 | 8 |
| 4036 | Akira Kimata | University of Tsukuba | Optimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials | Akira Kimata, Akihiko Nogami, Hiro Yamasaki, Tomohiro Ohigashi, Masahiko Gosho, Miyako Igarashi, Yukio Sekiguchi, Masaki Ieda, Hugh Calkins, Kazutaka Aonuma, Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials, Journal of Cardiology, 2021, ISSN 0914-5087, doi: 10.1016/j.jjcc.2020.12.010 | Boehringer Ingelheim | 2 | 2 |
| 4043 | Janneke van der Woude | Erasmus Medical Center | Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis | J A M Sleutjes, J E Roeters van Lennep, E Boersma, A C de Vries, C J van der Woude, P292 Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysis, Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S322–S323. doi: 10.1093/ecco-jcc/jjab076.416 | Pfizer | 1 | N/A |
| 4043 | Janneke van der Woude | Erasmus Medical Center | Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis | Sleutjes, JAM, Roeters van Lennep, JE, Boersma, E, et al. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther. 2021; 00: 1– 14. doi: 10.1111/apt.16580 | Pfizer | 6 | 4 |
| 4316 | Martin Okun | Fort Healthcare | Geospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis. | 268 Analysis of association between variation in ambient solar ultraviolet exposure and disease severity for patients with moderate-severe psoriasis Okun, T.S. et al. Journal of Investigative Dermatology, Volume 141, Issue 5, S48 doi: 10.1016/j.jid.2021.02.290 | AbbVie | 0 | N/A |
| 4330 | Laure Gossec | Sorbonne Université | Domains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i) | Duarte C, Santos EJF, Ferreira RJO, et al. Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients RMD Open 2021;7:e001539. doi: 10.1136/rmdopen-2020-001539 | Pfizer | 14 | 7 |
| 4918 | Nina Hilkens | Radboudumc Nijmegen | Association between blood pressure, blood pressure variability and the risk of post-stroke dementia | Hilkens, Nina A.; Klijn, Catharina J.M.; Richard, Edo Blood pressure, blood pressure variability and the risk of poststroke dementia, Journal of Hypertension: March 11, 2021 - Volume Publish Ahead of Print - Issue doi: 10.1097/HJH.0000000000002841 | Boehringer Ingelheim | 0 | 4 |
| 5073 | Philip Robinson | University of Queensland | Assessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial data | Tam, H.K.J., Nash, P. and Robinson, P.C. (2021), The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. ACR Open Rheumatology. doi: 10.1002/acr2.11312 | Pfizer | 5 | 2 |
| 5074 | Sebastian Zundler | University Hospital Erlangen | Evaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysis | Becker E, Dedden M, Gall C, et al. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut Published Online First: 30 August 2021. doi: 10.1136/gutjnl-2021-324868 | Takeda | 52 | 15 |
| 5086 | Junko Takeshita | University of Pennsylvania | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | 560 Racial/ethnic diversity in U.S. clinical trials for acne, atopic dermatitis, and psoriasis Sevagamoorthy, A. et al. Journal of Investigative Dermatology, Volume 141, Issue 5, S97 doi: 10.1016/j.jid.2021.02.587 | AbbVie, Lilly, Regeneron | 0 | N/A |
| 5095 | Mathilde Nijkeuter | University Medical Center Utrecht | Assessing bleeding risk in patients with cancer-associated thrombosis | de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, C Ruiz Artacho P, Vanassche T, Nijkeuter M. Estimating Bleeding Risk in Patients with Cancer-associated Thrombosis: External Validation of Existing Risk Scores and Development of a New Risk Score [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/estimating-bleeding-risk-in-patients-with-cancer-associated-thrombosis-external-validation-of-existing-risk-scores-and-development-of-a-new-risk-score/. Accessed July 23, 2021. | Daiichi Sankyo | 4 | 14 |
| 5095 | Mathilde Nijkeuter | University Medical Center Utrecht | Assessing bleeding risk in patients with cancer-associated thrombosis | de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, Ruiz Artacho PC, Vanassche T, Nijkeuter M. Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. Thromb Haemost. 2021 Sep 20. doi: 10.1055/s-0041-1735251 | Daiichi Sankyo | 4 | 14 |
| 5096 | Joo Sang Lee | Samsung Medical Center, South Korea | Harnessing genetic interactions to advance precision cancer medicine | Synthetic lethality-mediated precision oncology via the tumor transcriptome. Lee, Joo Sang et al. Cell, Volume 184, Issue 9, 2487 - 2502.e13. doi: 10.1016/j.cell.2021.03.030 | Tempus AI, Inc. | 132 | 48 |
| 5098 | Christopher Baethge | University of Cologne Medical School | Dose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysis | Rink L, Adams A, Braun C, Bschor T, Kuhr K, Baethge C. Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom 2021. doi: 10.1159/000520554 | Lilly | 3 | 6 |
| 5163 | Susan Bates | Columbia University Medical Center | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Keith Sigel, Mengxi Zhou, Yeun-Hee Anna Park, Tinaye Mutetwa, Girish Nadkarni, Celine Yeh, Paz Polak, Carlie Sigel, Thierry Conroy, Béata Juzyna, Mark Ychou, Tito Fojo, Juan P Wisnivesky, Susan E. Bates, Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans, Seminars in Oncology, 2021, ISSN 0093-7754. doi: 10.1053/j.seminoncol.2021.02.001 | Celgene Corporation | 1 | 7 |
| 5165 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat | Ghang B, Lee JS, Kim J, Yoo B. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: Another story of the CARES trial. J Rheum Dis 2021; 28(1):219. Abstract | Takeda | N/A | N/A |
| 5166 | Thomas Metkus | Johns Hopkins University School of Medicine | Severe sepsis in the cardiac intensive care unit: management strategies and outcomes | Dugan, Eunice; Stephens, R. Scott; Schulman, Steven; Metkus, Thomas 1205: Sepsis in the Cardiac Intensive Care Unit: Demographics and Outcomes, Critical Care Medicine: January 2021 - Volume 49 - Issue 1 - p 605 doi: 10.1097/01.ccm.0000730708.28818.5e | Lilly | 0 | N/A |
| 5166 | Thomas Metkus | Johns Hopkins University School of Medicine | Severe sepsis in the cardiac intensive care unit: management strategies and outcomes | Feldman, E. W., Dugan, E., Stephens, R. S., Schulman, S., Zakaria, S., & Metkus, T. (2021). Presentation and outcomes of sepsis in the cardiac intensive care unit. American Heart Journal Plus: Cardiology Research and Practice, 7, 100040. doi: 10.1016/j.ahjo.2021.100040 | Lilly | 1 | 1 |
| 5207 | Fasihul Khan | University of Nottingham | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | Khan FA, Stewart I, Saini G, Robinson KA, Jenkins RG. A systematic review of blood biomarkers with individual participant data meta-analysis of matrix-metalloproteinase-7 in IPF. Eur Respir J. 2021 Sep 29:2101612. PMID: 34588192. doi: 10.1183/13993003.01612-2021 | BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche | 9 | 20 |
| 5207 | Fasihul Khan | University of Nottingham | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | A systematic review and individual participant data meta-analysis of MMP-7 and outcomes in idiopathic pulmonary fibrosis. Fasihul Khan, Iain Stewart, Gauri Saini, Karen A Robinson, Gisli Jenkins. European Respiratory Journal Sep 2021, 58 (suppl 65) PA395; doi: 10.1183/13993003.congress-2021.PA395 | BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche | 3 | 20 |
| 5292 | Désirée van der Heijde | Leiden University Medical Center | Measurement properties of the instruments used in the outcome assessment of axial spondyloarthritis | Boel A, Navarro-Compán V, van der Heijde D. Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis. RMD Open 2021;7:e001839. doi: 10.1136/rmdopen-2021-001839 | UCB | 6 | 1 |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach | Duong S, Crowson C, Atkinson E, Athreya A, Davis J, Matteson E, Weinshilboum R, Wang L, Myasoedova E. Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https://acrabstracts.org/abstract/clinical-predictors-of-response-to-methotrexate-in-patients-with-rheumatoid-arthritis-a-machine-learning-approach-using-clinical-trial-data/ | Roche, UCB | 1 | 11 |
| 5456 | Terina Martinez | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Modeling informative drop out in a disease progression model of Duchenne Muscular Dystrophy. Rhoda Muse, Jane Larkindale, Sarah Kim, Stephan Schmidt, Juan Francisco Morales, Sudhir Sivakumaran, Ramona Belfiore-Oshan, Varun Aggarwal, Klaus Romero, Jackson Burton and Diane Corey. Statistics and PMx e.g. MBMA, Bayesian application/method, trial design, optimal design, machine learning, data mining. ACoP12 (2021) STPM-198 www.go-acop.org/?abstract=198 | CureDuchenne | N/A | N/A |
| 5456 | Terina Martinez | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | Ramona Belfiore-Oshan, Varun Aggarwal, Rhoda Muse, Sarah Kim, Stephan Schmidt, Juan Francisco Morales, Karthik Linganeni, Sudhir Sivakumaran, Diane Corey, Klaus Romero, Terina Martinez. Acceleration of clinical trial design in Duchenne Muscular Dystrophy building a model-based Clinical Trial Simulation Tool. The Muscular Dystrophy Association (MDA) Clinical & Scientific conference, March 13-16, 2022 (Abstract). https://mdaconference.org/node/1556 | CureDuchenne | N/A | N/A |
| 5567 | Neeraj Narula | Hamilton Health Sciences | Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn’s Disease: An EXTEND Post-Hoc Analysis | Narula N, Wong ECL, Colombel J, et alPredicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) Gut Published Online First: 25 March 2021. doi: 10.1136/gutjnl-2020-323799 | AbbVie | 9 | 8 |
| 5567 | Neeraj Narula | Hamilton Health Sciences | Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohn’s Disease: An EXTEND Post-Hoc Analysis | Sa467 THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD) PERFORMS BETTER THAN THE SES-CD FOR PREDICTION OF ENDOSCOPIC REMISSION IN CROHN'S DISEASE. Narula, Neeraj et al. Gastroenterology, Volume 160, Issue 6, S-509. doi: 10.1016/S0016-5085(21)01923-5 | AbbVie | 1 | N/A |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Hopkins AM, Kichenadasse G, Abuhelwa AY, McKinnon RA, Rowland A, Sorich MJ. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers. 2021; 13(5):1176. doi: 10.3390/cancers13051176 | Roche | 4 | 15 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Abuhelwa AY, Kichenadasse G, McKinnon RA, Rowland A, Hopkins AM, Sorich MJ. Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer. Cancers. 2021; 13(9):2001. doi: 10.3390/cancers13092001 | Roche | 3 | 11 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Hopkins, A.M., Kichenadasse, G., McKinnon, R.A. et al. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer (2021). doi: 10.1038/s41416-021-01606-4 | Roche | 117 | 33 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Hopkins, A. M., Abuhelwa, A. Y., McKinnon, R. A., Logan, J. M., Kichenadasse, G., Rowland, A., & Sorich, M. J. (2021). Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials. European Journal of Cancer. doi: 10.1016/j.ejca.2021.10.020 | Roche | 2 | 2 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Ahmad Y Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A McKinnon, Andrew Rowland, Michael J Sorich, Ashley M Hopkins. Enhanced Bellmunt risk score for survival prediction in urothelial carcinoma treated with immunotherapy. Clinical Genitourinary Cancer, 2021. doi: 10.1016/j.clgc.2021.11.010 | Roche | 3 | 9 |
| 5925 | Min Hwan Kim | Yonsei University College of Medicine | Analysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical response | On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study. Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jeeye Kim, Hyung Seok Park, Seho Park, Youngup Cho, Byeong-Woo Park, Seung Il Kim, Joon Jeong, and Joohyuk Sohn. Journal of Clinical Oncology 2021 39:15_suppl, 1066-1066. doi: 10.1200/JCO.2021.39.15_suppl.1066 | Pfizer | 1 | N/A |
| 5931 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial | Kayali, M., Abi Jaoude, J., Mohammed, M. et al. Post-mastectomy Radiation Therapy in Triple-Negative Breast Cancer Patients: Analysis of the BEATRICE Trial. Ann Surg Oncol 29, 460–466 (2022). doi: 10.1245/s10434-021-10511-2 | Roche | 4 | 6 |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritis | Abuhelwa AY, Foster DJR, Manning-Bennett A, et al. Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis. Therapeutic Advances in Musculoskeletal Disease. January 2021. doi: 10.1177/1759720X211009020 | Roche | 5 | 0 |
| 5935 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Zhou J, Wong AH, Wang H, et al. 329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials. Journal for ImmunoTherapy of Cancer 2021;9: doi: 10.1136/jitc-2021-SITC2021.329 | Roche | 1 | N/A |
| 5945 | Neeraj Narula | Hamilton Health Sciences | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Narula, N., Wong, E., Colombel, J. F., Riddell, R., Marshall, J., Reinisch, W., & Dulai, P. (2021). DOP03 Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in Ulcerative Colitis. Journal of Crohn’s and Colitis, 15(Supplement_1), S042–S043. doi: 10.1093/ecco-jcc/jjab073.042 | Takeda | 0 | 12 |
| 5945 | Neeraj Narula | Hamilton Health Sciences | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Narula, N., Wong, E. C., Colombel, J. F., Riddell, R., Marshall, J. K., Reinisch, W., & Dulai, P. S. (2021). Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Clinical Gastroenterology and Hepatology. Published. doi: 10.1016/j.cgh.2021.07.005 | Takeda | 1 | 12 |
| 5951 | Mathilde Nijkeuter | University Medical Center Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | de Winter MA, Dorresteijn JAN, Carrier M, Cohen AT, Hansen J-, Kaasjager HAH, Middeldorp S, Raskob GE,Sørensen HT, Visseren FLJ, Wells PS, Büller HR, Nijkeuter M. Individual Benefits and Harms of Extended Anticoagulation in Patients with Venous Thromboembolism: The VTE-PREDICT Model [abstract]. Res PractThromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/individual-benefi ts-and-harms-of-extended-anticoagulation-in-patients-with-venous-thromboembolism-the-vte-predict-model/. Accessed July 23, 2021. | Boehringer Ingelheim, Daiichi Sankyo | N/A | N/A |
| 5984 | David Baker | Queen Mary University of London | Exploring possibilities to improve the risk benefit balance through analysis of the ocrelizumab phase II extension study | David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson. Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2021; uxab015. doi: 10.1093/cei/uxab015 | Roche | 23 | 14 |
| 6062 | Alexander Meisel | University Hospital of Zurich | Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | Meisel, A., Mark, M., Haider, A., Holer, L., Hayoz, S., Gebhard, C., Bengs, S., Hochmair, M., Cappuzzo, F., Reck, M., von Moos, R., & Stenner-Liewen, F. (2021). 1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT). Annals of Oncology, 32, S996. doi: 10.1016/j.annonc.2021.08.1881. | Roche | 0 | N/A |
| 6064 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis | Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 Jul 28:S1542-3565(21)00820-X. PMID: 34329776. doi: 10.1016/j.cgh.2021.07.038 | Johnson & Johnson, Takeda | 31 | 8 |
| 6489 | Line Uhrenholt | Aalborg University Hospital | Tapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthritis: a systematic review of randomised controlled trials | Line Uhrenholt, Robin Christensen, Wilfred K H Dinesen, Caroline H Liboriussen, Stine S Andersen, Lene Dreyer, Annette Schlemmer, Ellen-Margrethe Hauge, Conni Skrubbeltrang, Peter C Taylor, Salome Kristensen. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology, 2021. doi: 10.1093/rheumatology/keab902 | AbbVie | 13 | 5 |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib. Modi, Natansh D. et al. The Breast, Volume 58, 57 – 62. doi: 10.1016/j.breast.2021.04.003 | Lilly | 11 | 4 |
| 6642 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohn’s Disease | Neeraj Narula, Emily C L Wong, Jean-Frederic Colombel, William J Sandborn, Marc Ferrante, John K Marshall, Walter Reinisch, Parambir S Dulai, Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn’s Disease, Journal of Crohn's and Colitis, Volume 16, Issue 4, April 2022, Pages 616–624. Doi:10.1093/ecco-jcc/jjab183 | AbbVie, Johnson & Johnson, Takeda | 1 | 1 |
| 6686 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool | Parambir S Dulai, MD, Emily C L Wong, BS, Walter Reinisch, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Neeraj Narula, MD, Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. Inflammatory Bowel Diseases, 2021; izab310, doi: 10.1093/ibd/izab310 | Takeda | 2 | 4 |
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetric Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | Frew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Dermal Tunnels Influence Time to Clinical Response and Family History Influences Time to Loss of Clinical Response in Hidradenitis Suppurativa Patients Treated with Adalimumab. Clinical and Experimental Dermatology. Accepted Author Manuscript. doi: 10.1111/ced.14448 | AbbVie | 0 | 7 |
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | Frew J, Jiang C, Singh N, Navrazhina K, Vaughan R, Krueger J, Quantifying the Natural Variation in Lesion Counts Over Time in Untreated Hidradenitis Suppurativa: Implications for Outcome Measures and Trial Design, JAAD International (2020), doi: 10.1016/j.jdin.2020.09.005 | AbbVie | 1 | 4 |
| 3369 | Michael Ward | National Institutes of Health (NIH) | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis | Wang R, Dasgupta A, Ward M. Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/predicting-major-treatment-response-to-tumor-necrosis-factor-inhibitorsin-patients-with-ankylosing-spondylitis/. | AbbVie, Pfizer | N/A | N/A |
| 4116 | Sharon Straus | St. Michael's Hospital | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis | Veroniki AA, Ashoor H, Rios P, Seitidis G, Mavridis D, Holroyd-Leduc J, Straus S, Tricco A. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: An individual patient data network meta-analysis. In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020;(9 Suppl 1):455. doi: 10.1002/14651858.CD202001 | AbbVie | 56 | 45 |
| 4117 | John Frew | Rockefeller University | Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa | Malignancy and Infection Risk During Adalimumab Therapy in Hidradenitis Suppurativa. Frew, J., Jiang, C., Singh, N., Grand, D., Navrazhina, K., Vaughan, R. and Krueger, J. (2020), Clin Exp Dermatol. Accepted Author Manuscript. doi: 10.1111/ced.14264 | AbbVie | 0 | 6 |
| 4319 | Maria Alice Franzoi | Jules Bordet Institut | Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials | 153P Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials. Franzoi, M.A. et al. Annals of Oncology, Volume 31, S71. doi: 10.1016/j.annonc.2020.03.253 | Lilly | 0 | N/A |
| 4319 | Maria Alice Franzoi | Jules Bordet Institut | Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy | Maria Alice Franzoi, MD, Daniel Eiger, MD, Lieveke Ameye, MSc, Noam Ponde, MD, Rafael Caparica, MD, Claudia De Angelis, MD, Mariana Brandão, MD, Christine Desmedt, PhD, Serena Di Cosimo, MD, Nuria Kotecki, MD, Matteo Lambertini, MD PhD, Ahmad Awada, MD PhD, Martine Piccart, MD PhD, Evandro de Azambuja, MD PhD, Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy, JNCI: Journal of the National Cancer Institute, djaa116, doi: 10.1093/jnci/djaa116 | Lilly | 15 | 18 |
| 4327 | Michael Szarek | SUNY Downstate Medical Center | Analysis of Total Events and Hospitalizations in the SPARCL Study | Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16. doi: 10.1016/j.jacc.2020.03.015 | Pfizer | 71 | 15 |
| 4540 | Chris Gale | University of Leeds | Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trial | Wilkinson, C., Wu, J., Searle, S.D. et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 18, 401 (2020). doi: 10.1186/s12916-020-01870-w | Daiichi Sankyo | 30 | 43 |
| 5895, 6117 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland and Michael J. Sorich. Clin Cancer Res October 15 2020 (26) (20) 5487-5493; doi: 10.1158/1078-0432.CCR-20-1876 | Roche | 111 | 43 |
| 5930 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer | Abi Jaoude J, Kayali M, de Azambuja E, Makki M, Tamim H, Tfayli A, El Saghir N, Geara F, Piccart M, Poortmans P, Zeidan YH. De-intensifying radiation therapy in HER-2 positive breast cancer: to boost or not to boost?. International Journal of Radiation Oncology-Biology-Physics. 2020 Nov 15;108(4):1040-6. doi : 10.1016/j.ijrobp.2020.06.078 | Roche | 23 | 2 |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol, baricitinib and tocilizumab used in the treatment of rheumatoid arthritis | Abuhelwa, A.Y., Hopkins, A.M., Sorich, M.J. et al. Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Sci Rep 10, 18634 (2020). doi: 10.1038/s41598-020-75673-7 | Roche | 1 | 11 |
| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Public Disclosure | Data Contributor(s) | Altmetric Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | Clinical Response Rates, Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post-Hoc Analysis of PIONEER 1 and 2 Individual Patient Data Frew, John W. et al. Journal of the American Academy of Dermatology, Volume 0, Issue 0 doi: 10.1016/j.jaad.2019.12.044 | AbbVie | 1 | 14 |
| 4036 | Akira Kimata | University of Tsukuba | Optimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials | Circulation. Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019, Volume: 140, Issue: 25, Pages: e965-e1011, DOI: (10.1161/CIR.0000000000000742) doi: 10.1161/CIR.0000000000000742 | Boehringer Ingelheim | 34 | 10 |